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ABSTRACT 
The thesis entitled "Analysis of antiulcer drugs with special 
reference to proton pump inhibitors in pharmaceutical 
formulations" is comprised of five chapters. The first chapter describes a 
general introduction of the subject matter. The very relevant matters 
include: 
• a brief history of drug and its relation with our daily life 
• importance of drug analysis and its role in testing the medicine before it 
is made available to the public 
• a note on drug impurity profiling 
• a brief description of various analytical techniques and its applications in 
the quantitation of drug in pharmaceuticals and biological fluids 
• a description on process monitoring and validation 
• a detailed information on statistical treatment of calibration data in 
order to facilitate the selection of parameters which are relevant to the 
performance and suitability of the given analytical procedure. 
Once the analytical method is advent, it is necessary to decide its 
suitability for the intended purpose. This is known as the method validation. 
Now a days, a variety of strict demands are posed by numerous 
international organizations namely International Union of Pure and Applied 
Chemistry, International Laboratory Accreditation Conference, Western 
European Laboratory Accreditation Cooperation, International Conference 
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on Harmonisation, and International Organization for Standardization on 
such methods, the most important parameters for evaluation of method 
reliability and overall performances are: 
• confirmation of identity 
• solution stability 
• selectivity/ specificity 
• linearity 
• accuracy and precision 
• limits of detection and quantitation 
• recovery 
• robustness/ruggedness 
• equivalence testing 
A description of the classification of drugs based on pharmacological 
action on human organs is included and finally a brief literature and 
chemical structures of the four drugs, i.e., pantoprazole, lansoprazole, 
esomeprazole magnesium and rabeprazole sodium are presented. An 
abundant and well-composed list of references is given at the end of this 
chapter, comprises 228 citations, taken from the world's leading scientific 
journals in the field. 
The second chapter describes a kinetic spectrophotometric method 
which is based on the oxidation of pantoprazole with Fe(III) in sulphuric 
acid medium. Fe(III) subsequently reduces to Fe(II), which is coupled with 
potassium ferricyanide to form Prussian blue. The reaction is followed 
spectrophotometrically by measuring the increase in absorbance with time 
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(1 - 8 min) at 725 nm. The initial rate method is adopted for constructing 
the calibration graph, which is linear in the concentration range of 5 - 90 ug 
ml"1. The regression analysis yields the calibration equation: 
v = 3.467 x 10"6 + 4.356 x 10"5 C. 
The limits of detection and quantitation are 1.46 and 4.43 u.g ml"1, 
respectively. The proposed method was optimized and validated both 
statistically and through recovery studies. The experimental true bias of all 
samples is < ±2.0%. The method has been successfully applied to the 
determination of pantoprazole in pharmaceutical preparations. 
In chapter three, a simple kinetic spectrophotometric method has been 
discussed for the determination of lansoprazole in pharmaceutical 
formulations. The method is based on the oxidation of the drug with 
alkaline potassium permanganate at room temperature. The reaction is 
followed spectrophotometrically by measuring increase in absorbance owing 
to the formation of Mn042" at 610 nm (Method A) and decrease in 
absorbance at 530 nm due to disappearance of MnO; (Method B). The 
calibration curves are linear over the concentration ranges of 5 - 150 and 5 
- 70 \xg ml"1 with the corresponding calibration equations: 
rate = -3.915 x 10'6 + 5.271 x 10~5 C 
and 
AA = 1.04 x 10~3 + 1.78 x 10"3 C 
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for methods A, and B, respectively. The statistical comparison of the results 
of the proposed procedures with those of the reference spectrophotometric 
method show excellent agreement and indicated no significant difference 
between the methods compared in terms of accuracy and precision. Interval 
hypothesis tests have also been performed which indicated that the true 
bias of all samples is less than ± 2%. 
The fourth chapter describes two simple and sensitive 
spectrophotometric methods for the determination of esomeprazole 
magnesium in commercial dosage forms. Method A is based on the reaction 
of esomeprazole magnesium with 5-sulphosalicylic acid in methanol to form 
a yellow product, which absorbs maximally at 365 nm. Method B utilizes the 
reaction of esomeprazole magnesium with N-bromosuccinimide in acetone-
chloroform medium to form a-bromo derivative of the drug peaking at 380 
nm. Under the optimized experimental conditions, Beer's law is obeyed in 
the concentration ranges of 2 - 48 and 10 - 100 \xg ml"1 with molar 
absorptivity of 2.11 x 104 and 4.57 x 1041 mol-1 cm"1 for methods A and B, 
respectively. The limits of detection for methods A and B are 0.35 and 0.46 
ug ml"1, respectively. No interference was observed from excipients 
commonly present in tablet formulations. Methods A and B are successfully 
applied to the commercial tablets for the estimation of esomeprazole 
magnesium with good accuracy and precision. The results are compared 
favorably with the reference spectrophotometric method indicating no 
significant difference between the methods compared. 
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The last chapter describes two selective and validated 
spectrophotometric methods have been described for the quantitation of 
rabeprazole sodium in commercial dosage forms. Method A is based on the 
reaction of drug with 3-methyl-2-benzothiazolinone hydrazone 
hydrochloride (MBTH) in the presence of ammonium cerium (IV) nitrate in 
acetic acid medium at room temperature to form red-brown product which 
absorbs maximally at 470 nm. Method B utilizes the reaction of rabeprazole 
sodium with l-chloro-2, 4-dinitrobenzene (CDNB) in dimethyl sulphoxide 
(DMSO) at 45 ± 1°C to form yellow coloured Meisenheimer complex. The 
coloured complex has a characteristic band peaking at 420 nm. Under the 
optimized reaction conditions, proposed methods are validated as per ICH 
guidelines. Beer's law is obeyed in the concentration ranges of 14 - 140 
and 7.5 - 165 ng ml"1 with linear regression equations: 
A = 6.041 x 10"4 + 1.07 x 10"2 C 
and 
A = 1.020 x 10"3+ 5.0 x 10"3C 
for methods A and B, respectively. The limits of detection for methods A 
and B are 1.38 and 0.75 ug ml'1, respectively. Both methods have been 
applied successfully for the quantitation of rabeprazole sodium in 
commercial dosage forms. The results are compared with the reference UV 
spectrophotometric method. 
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GENERAL INTRODUCTION 
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The discovery of new drugs and their development into commercial product 
takes place across the broad scope of the pharmaceutical industry. The basic 
underpinning for this effort is the cumulative body of scientific and biomedical 
information generated worldwide in research institutes, academic centers, and 
industries. The combined efforts of chemists, biologists, molecular biologists, 
pharmacologists, toxicologists and pharmaceutical scientists, engineers, and many 
others are involved in the drug discovery and development process. 
The pharmaceutical industry in the United States grew rapidly during World 
War II and in the years immediately following. The upsurge in the domestic 
production of the drugs and pharmaceutical products stemmed in part from the 
wartime hazards and consequent undependability of overseas shipping, the 
unavailability of drugs from previous sources, and the increased need for drugs of all 
kinds, but especially those with life-saving capabilities. One such drug is penicillin, 
the antibiotic that became commercially available in 1944, 15 years after its 
discovery in England by Sir Alexander Fleming and one year before the end of the 
war. 
New drugs may be discovered from a variety of natural sources or created 
synthetically in the laboratory. They may be discovered by accident or as the result 
of many years of tireless pursuit. Throughout history, plant materials have served as 
reservoir of potential new drugs. Yet, only a small portion of the approximate 
270,000 known plants thus far have been investigated for medicinal activity. Certain 
major contributions to modern drug therapy may be attributed to the successful 
conversion of botanic folklore remedies into modern wonder drugs. The chemical 
reserpine, a tranquilizer and hypertensive agent, is an example of a medicinal 
chemical isolated by design from the folklore remedy Rauwolfia serpentina. Another 
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plant drug, periwinkle or Vinca rosea, was first scientifically investigated as a result 
of its reputation in folklore as an agent useful in the treatment of diabetes mellitus. 
Plant extactives from Vinca rosea yielded two potent drugs, which when screened 
for pharmacological activity surprisingly exhibited antitumor capabilities. These two 
materials, vinblastine and vincristine, have been used successfully in the treatment 
of certain type of cancer including acute leukemia, Hodgkin's disease, lymphocytic 
lymphoma, and other malignancies. 
After the isolation and structural identification of active plant constituents, 
chemists may recreate them by total synthesis in the laboratory or more importantly 
use the natural chemical as the starting material in the creation of slightly different 
chemical structures through molecule manipulation procedures. The new structures, 
termed semisynthetic drugs, may have a slightly or vastly different pharmacological 
activity than the starting substance, depending on the nature and extent of chemical 
alteration. Other plant constituents that in themselves may be inactive or rather 
unimportant therapeutically may be chemically modified to yield important drugs 
with profound pharmacological activity. For example, the various species of 
Dioscorea popularly known as Mexican yams, are rich in the chemical steroid 
structure from which cortisone and estrogens are semisynthetically produced. 
Animals have served humans in their search for drugs in a number of ways. 
They not only have yielded to drug testing and biological assay procedures but also 
have provided drugs that are mannered from their tissues or though their biological 
processes. Hormonal substances such as thyroid extract, insulin, and pituitary 
hormone obtained from the endocrine glands of cattle, sheep, and swine are life-
saving drugs used daily as replacement therapy in the human body. The urine of 
pregnant mares is a rich source of estrogens. Knowledge of the structural 
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architecture of the individual hormonal substances has produced a variety of 
synthetic and semisynthetic compounds with hormone-like activity. The synthetic 
chemicals used as oral contraceptives are notable examples. 
The use of animals in the production of various biological products, including 
serums, antitoxins, and vaccines has been of life-saving significance ever since the 
pioneering work of Dr. Edward Jenner on the smallpox vaccine in England. Today 
the poliomyelitis vaccine is prepared in culture of renal monkey tissue, the mumps 
and influenza vaccines in fluids of chick embryo, the rubella (German measles) 
vaccine in duck embryo, and the smallpox vaccine from the skin of bovine calves 
inoculated with vaccinia virus. New vaccines for diseases as AIDS and cancer are 
being developed through the use of cell and tissue cultures. 
In recent years many new and important innovative therapeutic agents have 
been developed and approved by the Food and Drug Administration (USA), 
including drugs to treat: acquired immune deficiency syndrome (indinavir), 
refractory benign prostatic hyperplasia (sumatriptan), ovarian carcinoma 
(paclitaxel), gastric ulcers (lansoprazole, esomeprazole, rabeprazole, pantoprazole), 
hyperlipidemia (gemfibrozil), hypertension (enalapril), congestive heart failure 
(carvedalol), coronary artery disease (fluvastatin), obsessive compulsive disorders 
(fluoxetine), arthritis (nedocromil), ostioporosis (alendronate), male impotance 
(sindenafil), infectious disease (ciprofloxacin) and other diseases and conditions, 
with literally hundreds of potential therapeutic agents in various stages of clinical 
evaluation. 
We live today in a world of drugs: drugs for pain, drugs for disease, drugs for 
allergies, drugs for pleasure, and drugs for mental health. Drugs that have been 
rationally designed; drugs that have been synthesized in the factory or purified from 
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nature have been clinically tested. It was supposed that the drugs act on the human 
organ effectively and safely. By no means was it always so. Before the end of the 
19th century, medicines were concocted with a mixture of empiricism and prayer. 
Trial and error, inherited lore, or mystical theories were the basis of the world's 
pharmacopoeias. The technology of making drugs was crude at best: tinctures, 
poultices, soups, and teas were made with water or alcohol based extracts of freshly 
ground or dried herbs or animal products such as bone, fat, or even pearls, and 
sometimes from minerals best left in the ground - mercury among the favored. The 
difference between a poison and a medicine was a hazy differentiation at best: In the 
16th century, Paracelsus declared that the only difference between a medicine and a 
poison was in the dose. All medicines were toxic. There is no known drug that is not 
harmful or even poisonous at high doses. In theory, a "goal drug" would produce the 
specifically desired effect, be administered by the most desired route at minimal 
dosage and dosing frequency, have optimal onset and duration of activity, exhibit no 
side effects, and following its desired effect would be eliminated from the body 
efficiently, completely, and without residual effect. The gradual change from the use 
of natural products in their entire state to either purified extracts from those products 
or to synthetic chemically - produced substances can be said to have been taking 
place between the time of Paracelsus, who lived in Basel during the first half of the 
sixteenth century, to that of Ehrlich, to whom the award of a Nobel prize in 1909 
was a fitting reward for his remarkable researches and breakthrough during the first 
decade of this century. This period has been described as that leading from 
Quintessence to the Chemical and has been fascinatingly reviewed by H. J. Barber 
[1]. This transition from the Quintessence to the Chemical stimulated a very 
considerable amount of interest in the analysis as well as purity of natural products 
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to determine, as De Quincey [2] had said one hundred years earlier, not the apparent 
quantities as determined by weighing but the virtual quantities after allowing for the 
alloy of impurity. Thus, there is no doubt that nearly a century of pharmaceutical 
research has contributed spectacularly to improvement in human health and quality 
of life. 
The growing awareness of the need to analyze drug substances was also 
apparent before any synthetic materials found regular using medicine. Higher 
standards for the preparation of pharmaceutical ingredients had been set, following 
the 1858 Medical Act's stipulation that the General Medical Council (U.K.) should 
produce a list of medicines and compounds and manner of preparing them together 
with true weights and measures by which they are to be prepared and mixed [3]. The 
first editions of British Pharmacopoeia and Japanese Pharmacopoeia were published 
in 1864 and 1886, respectively. Thereafter, pharmaceutical and fine chemical 
manufacturers laid greater emphasis on meeting the standards set by 
pharmacopoeias. In 1890, Jesse Boot established an analytical laboratory and its 
staff were involved mainly for analyzing proprietary medicines of competitors in 
order that Boots should develop new and / or cheaper formulations [4]. 
The increase in use of classical analysis to quantitate and define materials used 
in medicine, together with the increase in the use of materials of synthetic origin and 
of increasing complexity, is evident from a study of pharmacopoeias of various 
countries issued between 1900 and 1950. Shortly after this period one can see the 
exciting beginnings of a completely new era in the analysis of drugs based on the 
introduction of new concepts of analytical methodology that found no reference in 
the classical analytical textbooks of the time. The introduction of complexometric 
and non-aqueous titrimetry in the early 1950s, gas liquid chromatography in 1952, 
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thin layer chromatography in 1956 together with the increasing applications of ultra-
violet and infra-red spectroscopy during this period, can all be followed in the pages 
of any national pharmacopoeia that was being published regularly during this period. 
This brings us to the early 1960s and at those times any regulatory interest in the 
quality of drugs rested almost entirely on the pharmacopoeias. 
In the European Community of countries, directives have been issued to 
ensure that the legislation in each member state shall provide for the comprehensive 
examination of intended drug materials before they are allowed to enter the market. 
Mutagenicity, carcinogenecity, toxicity, effect of reproductive function, 
pharmacodynamics and pharmacokinetics are among the properties to be studied and 
material must be unequivocally characterized with respect to the substance itself and 
the amounts of impurity that are likely to arise during the course of validated 
production processes. 
Purity has always been considered as an essential factor in ensuring drug 
quality. Presently drug analysis and pharmaceutical impurities are the subjects of 
constant review in the public interest. Pharmaceutical impurities are the unwanted 
chemicals that remain with the active pharmaceutical ingredients (APIs) or develop 
during formulation, or upon degradation of both API and formulated APIs to 
medicines [5]. The presence of these unwanted chemicals even in small amounts 
might influence the efficacy and safety of the pharmaceutical products. Therefore, 
for identification and quantification, the drug registration authorities have suggested 
the following steps: 
• The quality of starting materials, reagents and solvents used during synthesis, 
chemical reactions involved in the synthesis, reaction conditions, purification 
steps and storage of the final drug substance affect the impurity profile of a drug 
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substance. Any minor change in the above conditions may dramatically change 
the impurity profile. 
• It is required to detect impurities in drug substance obtained from batches 
manufactured during the development process, batches from the commercial 
process and stress conditions. 
• The structures of impurities should be elucidated when present at level higher 
than 0.1% or in some cases higher than 0.2%, depending on daily-recommended 
dosage. 
• The impurities are synthesized based on the suggested structures. 
• The synthesized impurities are used as an impurity standard for the 
development of a selective analytical method for its quantitation in drug 
substance and / or products. 
Impurities associated with APIs are classified into three groups for regulatory 
purposes as organic, inorganic and residual solvents [6]. 
• Organic impurities may arise from starting materials (most often from isomeric 
impurities), synthetic intermediates (incomplete reaction or excess reagent used), 
by-products, degradation products, reagents, ligands and catalysts. The reagents, 
ligands and catalysts are less commonly found in APIs; in some cases they may 
pose a problem as impurities. 
• Inorganic impurities present in pharmaceutical products originate from the 
equipment used and from reagents, catalysts, heavy metals, drying agents and 
filter aids. The chances of having impurities from reagents, ligands and catalysts 
are rare: however, in some processes, these could create a problem unless the 
manufacturers take proper care during production. The main sources of impurity 
of heavy metals are the water used in the processes and the reactors (if stainless 
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steel reactors are used), where acidification or acid hydrolysis takes place. These 
impurities of heavy metals can easily be avoided using demineralized water and 
glass-lined reactors. 
• Residual solvents and other volatile impurities must be detected and assayed, not 
only because of their potential toxicity and deleterious environmental effects, but 
also because they can impart undesirable organoleptic characteristics to drugs. 
Since residual solvents arise in excipients and occasionally in the manufacture of 
drug products. According to ICH guidelines, residual solvents can be grouped 
into three categories based on the possible risk to human health [6]. Category I 
incudes solvents such as benzene (2 ppm limit) and carbon tetrachloride (4 ppm 
limit). The solvents belong to Category II are methylene chloride (600 ppm 
limit), methanol (3000 ppm limit), pyridine (200 ppm limit), toluene (890 ppm 
limit), N,N-dimethyl formamide (880 ppm limit) and acetonitrile (410 ppm 
limit). The solvents of category II are most commonly used during the 
manufacturing process. Acetic acid, acetone, isopropyl alcohol, butanol, ethanol 
and ethyl acetate are solvents of category III. These solvents have higher 
tolerance limits. ICH guidelines [7] have recommended daily exposures of 50 
mg or less per day. 
ICH guidelines achieved a great deal in harmonizing the definitions of the 
impurities in new drug substances. It is necessary to perform all the investigations 
on appropriate reference standards of drugs and impurities to get meaningful 
specifications. In order to meet the challenges to ensure high degree of purity of 
drug substances and drug products, a scheme is proposed for profiling drug impurity 
(Fig. 1.1). 
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Fig. 1.1. Proposed chart for profiling drug impurity. 
11 
Over the last 30 years, the very existence of searching analytical methods has 
contributed quite considerably to an improvement in the general quality of the drugs. 
We are all familiar with adage that "Quality must be built into a product - it can 
never be analyzed into it". The most frequently used analytical techniques in 
pharmaceutical analysis are titrimetry, chromatography, electrochemical methods 
and spectroscopy. Sometimes these techniques are combined with other supporting/ 
subsidiary instruments like flow injection analysis system or kinetic type of analysis. 
Thus making them more sensitive, selective and fast. 
In the field of drug analysis volumetric methods, either direct or indirect, have 
their own importance due to their inherent simplicity. This is the reason why still a 
number of official methods for the determination of pharmaceuticals in the 
pharmacopocieas are based on titrimetry. Though it is the oldest technique in the 
market now but still having their recognition in the field of scientific research. 
Recently titrimetric methods have been used for the determination of albendazole 
[8], gatifloxacin [9], promethazine theodate [10] and procaine hydrochloride [11] in 
commercial dosage forms. 
Chromatographic methods have many applications in trace analysis and 
sometimes prove it as the only way. Chromatography is used extensively in the 
pharmaceutical industry as a separation tool for qualitative and quantitative analysis 
of various pharmaceutical compounds and drugs [12]. The different types of 
chromatography such as thin layer chromatography, high performance thin layer 
chromatography, column chromatography, high performance liquid 
chromatography, gas chromatography and capillary electro-chromatography have 
most frequently used in the field of pharmaceutical as well as biom#4^iarialyses. 
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Thin layer chromatography (TLC) has enjoyed widespread popularity in 
modern pharmaceutical analysis because of its simplicity, requires minimal 
instrumentation, laboratory space and maintenance. However, to achieve good 
precision, accuracy, reproducibility and speed of analysis, a certain degree of 
instrumentation is required: the use of densitometric evaluation is necessary at least 
for quantification [13-17]. A TLC method has been developed for the quantitation of 
theophylline in plasma using plates coated with silica gel 60 F254 [18]. In an effort, 
resolution of three commonly used |3-blockers, (±) atenolol, (±) metoprolol and (±) 
propranolol, into their enantiomers has been achieved using normal-phase TLC on 
silica gel G plates impregnated with L-aspartic acid as the chiral selector with 
different combinations of acetonitrile-methanol-water as mobile phase [19]. Thin 
layer chromatography has also been employed to identify an unknown compound in 
hydroquinine that has a higher Rf value and forms during migration when 
dichloromethane and methanol are used as the development solvent [20]. The level 
of quinine, cinchonine and cinconidine in natural products and marketed 
formulations has been determined by TLC in combination with fluorescence 
enhanced detection [21]. This technique has also been used to analyse polymyxin B, 
framycetin, and dexamethasone in an ointment [22] and the contents of drotaverine 
and nifuroxazide in capsules [23]. 
High performance thin layer chromatography (HPTLC) is an Off-Line 
technique whose every stage of analysis can be visualized. It is a relatively young 
thin-layer technique, which is still undergoing improvements and gaining the 
popularity. The advantages [24] of HPTLC are given below: 
• simple to handle the instrument 
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• short analysis time to analyze complex or crude samples with minimum sample 
clean up 
• optimized coating material with a separation power superior to that of the best 
HPLC separation material 
• an improved method of feeding the mobile phase 
• evaluate the entire chromatogram with a wide variety of techniques and 
parameters without time constraints 
• simultaneous but independent development of multiple sample and standards on 
each plate, leading to an increased reliability of results (in-system calibrations) 
• robustness for easy transfer of samples. 
Several drugs have been successfully investigated by HPTLC in pharmaceutical 
preparations [25-28]. 
At present, HPLC is the most widely used technique for the analysis of bulk 
drugs and their formulations [29,30]. Derivatization of the drugs prior to analysis is 
normally not required. The sample preparation is extremely simple and the errors 
associated with it are generally kept to a minimum by using HPLC. Gradient elution, 
temperature and wavelength-programming techniques provide valuable information 
regarding the undetected components of a given drug. Generally speaking, gradient 
elution, although extensively used in pharmaceutical research, is not popular 
because many of the above advantages are lost. Instead, screening for potential 
impurities is often performed by a combination of isocratic HPLC methods. For 
example the search for 11 potential impurities of mizolastine required the use of 
three isocratic HPLC methods because of the large difference in the 
hydrophobicities of the impurities [31]. The choice of proper detection mode is 
crucial to ensure that all the components are detected. With UV detection, this 
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problem could be overcome by using a multiple wavelength-scanning program, 
which is capable of monitoring several wavelengths simultaneously. It provides 
assurance that all the UV- absorbing components are detected, if present in sufficient 
quality. Chiral detectors are useful in determining the purity of enantiomeric drugs 
by HPLC. Several books and articles have dealt the theory and practices of HPLC 
[32,33]. Many research papers have described the latest developments in its 
instrumentation and applications in the pharmaceutical industries [34,35]. However, 
the limitations of HPLC include the cost of columns, solvents and a lack of long-
term reproducibility due to the proprietary nature of column packings. 
Because of the specificity and sensitivity afforded by gas chromatography 
(GC), it has been widely used for the detection and determination of pharmaceuticals 
in dosage forms and biological fluids [36-39]. The use of mass spectrometer (MS) as 
the gas chromatographic detector provides additional sensitivity and specificity over 
other analytical techniques [40]. Gas chromatography-mass spectrometry is utilized 
for monitoring anticancer drugs [41] and also used for the determination of ramipril 
and ramiprilat in human plasma and urine [42]. Trace level contaminants in pure 
substances can also be determined by GC / MS [43]. 
Capillary electrophoresis (CE) is a relatively new analytical technique based 
on the separation of charged analytes through a small capillary under the influence 
of an electric field. It is based on a separation mechanism, which differs from all 
types of chromatography, which makes it either a potential alternative analytical 
technique capable of faster analysis and higher efficiency than HPLC, or 
complimentary technique to HPLC to augment the information obtained from the 
analysis. Thus, CE is becoming a powerful separation technique for large and small 
molecules, which can be organic and inorganic [44]. It has found several 
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applications in pharmaceutical analysis [45-51]. Different modes of CE such as 
capillary zone electrophoresis [52,53], micellar electrokinetic chromatography 
[54,55], isotachophoresis [56,57], capillary-electrokinetic [58,59], capillary gel 
electrophoresis [60,61], iso-electric focusing [62,63] and affinity capillary 
electrophoresis [64, 65] have been developed and applied for pharmaceutical purity 
testing and in bioanalysis of drugs. 
The use of electrochemical methods for the analysis of drugs and other 
compounds of biological interest has increased greatly over the last few years. This 
is due to the availability of a wide variety of electrode materials, electrochemical 
cells, electrochemical instruments, and electrochemical techniques that can be used 
with convenience and reliability are now commercially available. Electrochemical 
methods are characterized by high sensitivity, selectivity and accuracy. 
Pharmaceuticals containing phenolic, amino, heterocyclic nitrogen, ketonic or 
aldehyde group undergo oxidation at their characteristic potentials and hence 
selectivity of the technique is increased. Important electrochemical techniques such 
as amperometry, conductometry, potentiometry, polarography, differential pulse 
voltammetry, square wave voltammetry, cyclic voltammetry, anodic and cathodic 
stripping voltammetry have been used in drug analysis [66]. Potentiometric titrations 
are also reported in the pharmacopoeia as the standard method for the determination 
of certain drug substances [67-69]. Despite the wide use of spectrometry and 
chromatography, analysts are choosing polarography and voltammetry [70-75] as an 
alternative due to their selectivity and sensitivity. 
Spectroscopic methods are widely used for the assay of drugs in 
pharmaceutical formulations. The simplicity of UV-spectrophotometry is known and 
most widely accepted for qualitative and quantitative analysis and in structure 
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identification. UV- spectrophotometry, usually, does not require elaborate sample 
preparation steps prior to assay. Therefore, the sample can be recovered for further 
testing or subsequent analytical procedures. However, these methods are inadequate 
when two or more drugs showing similar UV spectra in the presence of other 
components present in the drug sample like excipients or decomposition products. 
The use of UV-spectrophotometry for drug analysis in pharmaceutical prepartions 
has been increased rapidly in the last few years [76-79]. 
Photometric methods of analysis are performed in the visible region of light. 
These methods are usually based on the following aspects: 
• complex-formation reaction 
• oxidation-reduction process 
• a catalytic effect 
In each type of reaction the absorbance of coloured compounds is measured. 
Usually the analyte under investigation being colourless, they are reacted with 
suitable chemical reagents in order to convert them in coloured compounds. Simple 
colourimetric and UV methods continue to be popular for carrying out single-
component assays on a variety of formulated products. The examples of UV-visible 
spectrophotometric methods for the quantiation of pharmaceutical compounds that 
have been published [80-124] are given in Table 1.1. 
In the course of this discussion, the importance of computer-aided 
spectrophotometric determination of multicomponent systems cannot by ignored. 
Pharmaceutical preparations are usually mixtures of the active principle and various 
excipients that absorb in the same region as the component of interest, thereby 
resulting in band overlap and impending the use of the technique with simple 
calibration methods. The inception of microcomputers and spectrophotometers that 
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Table 1.1 
Quantitative analysis of drugs in pharmaceutical formulations by UV-visible 
spectrophotometric procedures 
Name of drug Reagents used Mnax (nm) References 
Acetoaminophen 
Amiodarone HCI 
Amlodipine besylate 
Amoxycillin 
ampicillin 
& 
Ampicillin, amoxycillin 
& carbenicillin 
Ascorbic acid 
Benidipine HCI 
Captopril 
Diclofenac sodium 
Diltiazem HCI 
Famotidine 
Flunarizine 
dihydrochloride 
Irbesartan 
Lisinopril 
Labetalol HCI 
Losartan potassium 
m-Cresol 
p-Chloranilic acid 
2,3-Dichloro 5,6- dicyano 
1,4- benzoquinone 
p-Chloranilic acid 
Ninhydrin in DMF medium 
2,3-Dichloro 5,6- dicyano 
1,4- benzoquinone 
Ascorbic acid 
KI03 
Folin ciocalteau phenol 
1 -Chloro-2,4-dinitrobenzene 
Methanol 
KIO3 in HCI medium 
Tris buffer 
Sodium metavanadate 
Bromothymol blue 
Bromophenol blue 
Bromocresol green 
KMn04 in alkaline medium 
Ninhydrin 
Iodine 
Potassium iodate and iodide in 
aqueous medium 
7,7,8,8-Tetracyanoquinodimethane 
p-Chloranilic acid 
Ninhydrin 
Ascorbic acid 
Sodium nitroprusside & 
hydroxylamine hydrochloride 
KMn04 in alkaline medium 
640 
535 
575 
540 
595 
580 
530 
520 
750,770 
&750 
380 
238 
510 
284,305 
750 
415 
415 
415 
610 
590 
295,355 
80 
81 
81 
82 
83 
84 
84 
85 
86 
87 
88 
89 
90 
91 
92 
92 
92 
93 
94 
95 
352 
743 
525 
595 
530 
695 
603 
96 
97 
97 
98 
98 
99 
100 
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Levodopa 
Methyldopa 
L-dopa 
Menadione 
Metoprolol tartrate 
Mometasone furoate 
Nalidixic acid 
Nicorandil 
Nifedipine 
Norfloxacin 
Carbinoxamine 
Pantoprazole sodium 
Perindopril erbumine 
Ramipril 
Silymarin 
Trimethoprim 
Thyroxine 
Verapamil HC1 
Ce(IV) nitrate in H2S04 medium 
Ce(IV) nitrate in H2S04 medium 
NaOH 
NaOH in the presence of amine 
KM11O4 in alkaline medium 
Ninhydrin 
Methanol 
Persulfate in alkaline medium 
Brucine-sulfanilic acid in H2S04 
medium 
3-Methyl-2-benzothiazoline 
hydrazone HCl-metol 
KMn04 in neutral medium 
4-Methyl amino phenol and K2Cr207 
Bromocresol green 
Bromophenol blue 
Bromothymol blue 
Eriochrome Black T 
KOH in dimethylsulphoxide 
Ammonium molybdate 
KMn04 in alkaline medium 
Cu (II) & eosin 
Potassium ferricyanide and 
ammonium ferric sulphate 
l-Chloro-2,4-dinitrobenzene in 
dimethyl sulphoxide 
Potassium iodate and potassium 
iodide in aqueous medium 
KMn04 in neutral medium 
3-Methyl-2-benzothiazoline 
hydrazone & potassium persulphate 
Persulphate in alkaline medium 
Nitrous acid 
Chloramine T 
N-Bromosuccinimide 
Potassium metaperiodate 
Tropaeolin 000 No. 1 
510 
550 
300 
450 
610 
595 
248 
320,390 
410 
101 
101 
102 
103 
104 
105 
106 
107 
108 
560 108 
530 
525 
415 
415 
415 
520 
430 
830 
603 
538 
725 
420 
352 
530 
430 
355 
420 
425 
415 
425 
400 
109 
110 
111 
111 
111 
111 
112 
112 
113 
114 
115 
116 
117 
118 
119 
120 
121 
122 
123 
124 
124 
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allow absorbance spectra to be expeditiously recorded at many wavelengths has 
enable the development of analytical methods based on the mathematical resolution 
of multivariate signals for the rapid quantitation of mixtures of analytes in control 
analyses. The application of multivariate calibration methods to spectral data in the 
biomedical and pharmaceutical fields has acquired a routine nature [125-128]. 
Partial least square has become the de facto standard for multivariate 
calibration because of the quality of the obtained calibration models, the ease of its 
implementation and the availability of software [129]. It shows the advantage of 
using full spectra, which is critical for the spectroscopic resolution of complex 
mixtures of analytes. It allows for a rapid determination of components, usually with 
no need of a prior separation. An additional advantage of robust multivariate 
methods is that calibration can be performed by ignoring the concentration of all 
other components except the analyte of interest. This makes these methods 
especially appealing for the determination of the active components in ophthalmic 
and nasal solutions as well as in the syrups, whose excipients may show absorption 
spectra that are severely overlapped with those from the analytes. The 
complementary use of partial least square multivariate calibration and artificial 
neural networks for the simultaneous spectrophotometric determination of three 
active components such as chlorpheniramine, nephazoline and dexamethasone in a 
pharmaceutical formulation has been successfully explored [130]. 
Difference spectrophotometry is an important and useful technique used in the 
determination of medicinal substances by eliminating specific interference from the 
degradation products, co-formulated drugs and non-specific irrelevant absorption 
from the formulation matrix. The technique involves reproducible attraction of the 
spectral properties of the absorbance difference between two solutions, provided that 
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the absorbance of the other absorbing substance is not affected by the reagent(s) 
used to alter the spectral property [131]. 
Near infra red (NIR) spectroscopy is a technique, which has found its way into 
pharmaceutical control laboratories in recent years for raw material identification, 
water analysis, and other pharmaceutical analyses [132-137]. There are several 
advantages associated with this technique such as reduction in the cost of testing, 
require no reagents, associated reagents preparation steps, sampling preparation 
steps and generally require only one working analyst day to complete testing. The 
US pharmacopoeia has proposed guidelines [138,139] for this technique. 
Nuclear magnetic resonance (NMR) spectroscopy has been mainly used for 
the elucidation and confirmation of structures. For the last decade, NMR methods 
have been introduced to quantitative analysis in order to determine the impurity 
profile of a drug, to characterize the composition of drug products in body fluids, in 
solid state measurements to provide the information about polymorphism of drug 
powders, quantification of drugs in tablets [140-146] and for micro-imaging to study 
the dissolution of tablets [147-149]. 
Fluorimetry and phosphorimetry find wide applications in quantitative studies 
of rates of degradation, metabolism, and excretion of drugs where other analytical 
techniques are not sufficiently sensitive. A gradual increase in the number of papers 
on the potential applications of fluoimetry and phosphorimetry in the field of 
pharmaceutical analysis has been noticed during the last few years [150-153]. 
The analytical measurement of elemental concentrations is important for the 
analysis of the major and minor constituents of pharmaceutical products. Metals are 
the major constituents of several pharmaceuticals such as dialysis solutions, lithium 
carbonate tablets, antacids and multi-vitamin and mineral tablets. The metal ions in 
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pharmaceuticals are determined more accurately and conveniently by atomic 
absorption spectrometry. The use of atomic absorption spectrometry in this regard 
has been the subject of several reviews and papers [154-159]. 
In the recent period, analysts are much interested in coupling the 
chromatographic techniques with spectroscopic techniques. The advent of liquid 
chromatography with mass spectrometry [160-162], gas chromatography with 
tandem mass spectrometry and liquid chromatography-electrospray tandem mass 
spectrometry are good examples. Hirsch and coworkers have determined the 
antibiotics using chromatography-electrospray tandem mass spectrometry [163]. 
Dielectric relaxation spectroscopy and X-ray powder diffractometry are also utilized 
for the identification of pharmaceuticals [164]. 
One of the significant analytical developments in the last two decades has 
been the wide spread utilization of flow injection analysis (FIA) assay of drugs in 
pharmaceutical laboratories. It has several advantages: 
• reduced reagent consumption 
• high sampling frequency 
• safety in applying toxic reagents because the whole analysis proceeds in a closed 
system 
An additional advantage observed in flow injection analysis is increased selectivity 
when the analyte is accompanied by more slowly reacting compound. This 
technique has been utilized successfully in the determination of some compounds of 
pharmaceutical interest [165-170]. 
Kinetic automatic methods are good choices for drug analyses as they permit 
sensitive and selective determination of many drugs within a few seconds with no 
pretreatment. The principles and applications of the kinetic methods have been 
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reviewed [171-173]. Essentially, kinetic methods rely on the measurements of 
concentration changes (detected via signal changes) in a reactant (which may be the 
analyte itself) with time after the sample and reagents have been mixed. The sample 
and reagent can be mixed manually or automatically. Only slow enough reaction 
tolerate manual mixing and even so, they are better handled automatically, not only 
to obtain more rapid and reproducible results, but also to increase the reaction rate in 
some cases. There are several approaches that can be used for the determination of 
single components in the absence of any kinetic interference (Table 1.2). However 
fixed-time and initial rate methods have been used more frequently for the 
determination of drugs in pharmaceutical formulations and biological fluids [174-
177]. Kinetic automatic techniques are generally based on open systems among the 
most popular of which are stopped flow system [178] and the continuous addition of 
reagent (CAR) technique [179-181]. Several drugs have been determined by using 
the CAR technique with photometric [182,183] and fiuorimetric detection [184]. 
The use of catalysts to accelerate analytical reactions is feasible with both reaction 
rate and equilibrium determinations. In this concern, the use of micellar media in 
kinetic method is recently encouraged to enhance the rate of reaction (through 
micellar catalysis) and may additionally improve the sensitivity and selectivity 
which in turn reduce the analysis time for the analyte [185-187]. Multicomponent 
kinetic determinations, often called as differential rate methods, are also receiving 
popularity in the field of pharmaceutical research [188,189]. Two new approaches 
i.e. kinetic wavelength pair method [190] and H-point standard addition method 
[191] have been proposed for dealing with overlapping spectra of components in the 
binary mixtures. 
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Table 1.2 
Single-component methods wi 
A. Direct-computation methods 
1. Integral methods 
a. Fixed-time 
i. One-point 
ii. Two-point 
iii. Multipoint 
b. Variable-time 
i. One-point 
ii. Two-point 
2. Rate methods 
a. Initial-rate 
b. Intermediate-rate 
3. Integrated-signal methods 
error compensation 
B. Curve-fitting methods 
1. Integral methods 
a. Linear responses 
b. Non-linear response 
i. Direct computation 
ii. Predictive (extrapolation) 
2. Rate methods 
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Whenever the question of mathematical and statistical treatment arises, the 
role of chemometrics cannot be ignored. Chemometrics is the chemical discipline 
concerned with the application of mathematical, statistical methods as well as those 
other methods based on mathematical logic to chemistry in order to design or select 
optimal procedures and experiments, and provide maximum chemical information 
by analyzing chemical data [192,193]. Several reviews have been reported on 
applications of chemometric methods in biomedical and pharmaceutical analysis 
[194-198]. 
PROCESS MONITORING AND VALIDATION 
Before an analytical method can be used for routine analysis, it must first be 
demonstrated that the method fulfills certain performance criteria. When this has 
been documented, the method is said to be validated. In order to address the 
performances of the analytical procedure adequately, the analyst is responsible to 
identify the relevant parameters, to design the experimental validation studies and 
define the appropriate acceptance criteria. The purpose of method validation is to 
establish that an accurate precise and rugged method has been developed. The 
process for the development, validation and use of analytical method is shown in 
Fig. 1.2. 
The ability to provide timely, accurate, and reliable data is central to the role 
of analytical chemists and is especially true in discovery, development and 
manufacture of pharmaceuticals. Analytical data are used to screen potential drug 
candidates, aid in the development of drug synthesis, support formulation studies, 
monitor the stability of bulk pharmaceuticals and formulated products, and test final 
products for release. The quality of analytical data is a key factor in the success of a 
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Calibration model, 
range and linearity 
Define performance 
specifications 
"< r 
Devise development 
experiments 
^ r 
Execute and 
evaluate results 
I 
Plan method validation 
experiments 
1 
Precision and accuracy 
Collate results 
Analyte stability 
Write validation report 
Apply validated 
method 
Fig. 1.2. The process of development, validation and routine use 
of an analytical method. 
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drug development programme. The process of method development and validation 
has a direct impact on the quality of these data. 
Several International Organizations and Regulatory Authorities, which are 
involved in fixing the criteria for the validations, are listed in Table 1.3. In the field 
of analysis, it is very clear that the definitions cover the entire field of analytical 
chemistry from bioanalysis to substance and product analysis. It has been agreed that 
the parameters for evaluation of method reliability and overall performances are: 
• confirmation of identity 
• solution stability 
• selectivity/ specificity 
• linearity 
• accuracy and precision 
• limits of detection and quantitation 
• recovery 
• robustness/ ruggedness 
• equivalence testing 
The overall validation strategy consists of four components, which are 
prevalidation, validation proper, study proper and statistical analysis. 
Among all of the International Organizations, the ICH guidelines achieved a 
great deal in harmonising the definitions of the required validation characteristics 
and their basic requirements. The International Conference on Harmonisation of the 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 
has harmonized the requirements in two guidelines [199,200]. The first one 
summarizes and defines the validation characteristics needed for various types of 
27 
Table 1.3 
Validation of analytical methods: International definitions 
Organization Applicability Remarks 
IUPAC Worldwide 
ILAC Worldwide 
WELAC Europe 
ICH Europe, Japan, USA Only pharmaceutical products 
ISO Worldwide Lack definition of selectivity and specificity 
Abbreviations: 
IUPAC, International Union of Pure and Applied Chemistry 
ILAC, International Laboratory Accreditation Conference 
WELAC, Western European Laboratory Accreditation Co-operation 
ICH, International Conference on Harmonisation 
ISO, International Organization for Standardization 
28 
test procedure. The second one extends the previous test to include the experimental 
data required and some statistical interpretation. These guidelines serve as a basis 
worldwide both for regulatory authorities and industries and bring the importance of 
a proper validation to the attention of all those involved in the process submission. 
In order to fulfill the validation responsibilities properly, the background of the 
validation parameters and their consequences must be understood. The validation 
characteristics and their minimum number of determinations required if applicable 
are given in Table 1.4 [200]. 
Confirmation of identity 
In general analytical methods consist of a measurement stage, which may be 
preceded by an isolation stage. It is necessary to establish that the signal or reaction 
produced at measurement stage is only due to the analyte and not due to something 
chemically or physically similar or arising as a coincidence. This is the confirmation 
of identity. Whether or not other compounds interfere with the measurement of the 
analyte will depend on the effectiveness of the isolation stage if it was part of the 
method, as well as the specificity/ selectivity of the measurement stage. 
Selectivity/ specificity 
There has been some controversy regarding the technical term for this 
validation characteristic i.e. specificity versus selectivity [201]. The terms selectivity 
and specificity are often used interchangeably. A detailed discussion of these terms 
as defined by different organizations has been made by Vessman [202]. 
The term specific generally refers to a method that produces a response for a 
single analyte only while the term selective refers to a method, which provides 
responses for a number of chemical entities that may or may not be distinguished 
from each other. If the response is distinguished from all other responses the method 
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Table 1.4 
Validation characteristics normally evaluated for the different types of test procedure 
[199] and the minimum number of determinations required (if applicable) [200] 
Validation 
characteristics 
Specificityb 
Linearity 
Range 
Accuracy 
Precision 
Repeatability 
Intermediate 
Precision/ rep-
roducibility0 
Detection limit 
Quantitation 
limit 
Minimum 
number 
. 
5 concentrations 
-
9 determinations 
over 3 concen-
tration levels 
(e.g. 3 X 3) 
6 determinations 
at 100% or 
9 determinations 
over 3 concen-
tration levels 
(e.g. 3 X 3) 
2-series 
-
-
Test procedure 
Identity Impurities 
Yes 
No 
No 
No 
No 
No 
No 
No 
Quantitative 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Nod 
Yes 
Limit 
Yes 
No 
No 
No 
No 
No 
Yes 
No 
Assay" 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
including dissolution, content potency 
Lack of specificity of one analytical procedure could be compensated by other 
supporting analytical procedure (s). 
intermediate precision sufficient for submission. 
May be needed in some cases. 
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is said to be selective. Since there are very few methods that respond to only one 
analyte, the term selectivity is usually more appropriate. 
In addition, where it is unclear whether or not the interferences are already 
present, the selectivity of the method can be investigated by studying its ability to 
measure, compared to other independent method/ techniques. These parameters 
apply to both qualitative and quantitative analysis. 
Accuracy and precision 
Accuracy expresses the closeness of a result to a true value. Method validation 
seeks to quantify the likely accuracy of the results by assessing systematic and 
random effects on results. Accuracy is, therefore, normally studied as two 
components: 'trueness' and 'precision'. The trueness (of a method) is an expression 
of how close the mean of a set of results (produced by the method) is to the true 
value. Trueness is normally expressed quantitatively in terms of "bias" which 
provides a measure of systematic or determinate error of an analytical method. 
Precision is a measure of how close results are to one another, and is usually 
expressed in terms of standard deviation, relative standard deviation and variance. 
Generally, the precision of an analytical method is readily obtained by simply 
repeating the measurements. The two most common precisions are: 
• repeatability (Intra day assay) 
• reproducibility (Inter day assay) 
They represent two extreme measure of precision, which can be obtained. 
Repeatability, also termed 'Intra day assay' precision (the smallest expected 
precision) will give an idea of the sort of variability to be expected when a method is 
performed by a single analyst on one piece of equipment over a short time scale by 
applying the whole analytical procedure to the sample i.e. the sort of variability to be 
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expected between the results when a sample is analysed in duplicate. If a sample is 
to be analysed by a number of laboratories for comparative purposes then a more 
meaningful precision measure is reproducibility (this is the largest measure of 
precision normally encountered). It is also termed as 'Inter day assay'. Both 
repeatability and reproducibility are generally dependent on analyte concentration, 
and should be determined at different concentration levels and if relevant, the 
relationship between precision and analyte concentration should be established. 
Repeatability and intermediate precision can be calculated by an analysis of 
variances [203,204]. No acceptance limit for accuracy and precision for an assay 
method is reported in the main regulatory guidelines [205,200,206], and only a 
document of the European community commission deals with the performance of 
analytical methods and the interpratation of results [207]. Several approaches 
discussed in the ICH guideline are given in Table 1.5. 
Linearity and calibration curve 
The linearity of an analytical method is its ability to elicit test results that are 
directly, or by means of well-defined mathematical transformation, proportional to 
the concentration of analytes in samples within a given range, is widely used in 
pharmaceutical analysis [208]. 
Acceptability of linearity data is often judged by examining the correlation 
coefficient and y-intercept of the linear regression line for the response versus 
concentration plot. A correlation coefficient of >0.999 is generally considered as 
evidence of acceptable fit of data to the regression line. The y-intercept should be 
less than a few percent of the response obtained for the analyte at the target level. 
The requirements and relevant parameter for the various calibrations are given in 
Table 1.6. 
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Table 1.5 
Quantitative approaches to demonstrate accuracy according to ICH [200] 
Drug substance Application of the analytical procedure to a reference material. 
Comparison of the results with those of a second, well 
characteristic procedure. 
Drug Product Application of the analytical procedure to synthetic mixtures of 
drug product components. 
Spiking of analyt to drug product. 
Comparison of the results with those of a second, well characterized 
procedure. 
Impurities Spiking of the impurity to drug substances or product, 
(quantitative) Comparison of the results with those of a second, well characterized 
procedure. 
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Table 1.6 
Requirements for different calibration modes with relevant parameters 
Quantitation Requirements Relevant parameters 
Single-point calibration 
External standard 
Multiple-point 
calibration 
Linear, unweighted 
Linear, weighted 
Linear function 
Non-significant 
ordinate intercept 
Homogenity of 
variances" 
Linear function 
Homogenity of 
variances3 
Linear function 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
statistical tests (vs. quadratic 
regression). 
Inclusion of zero in confidence 
interval of the ordinate intercept, 
magnitude of the intercept (as 
percent of the signal 100% test 
concentration). 
F-test of the variances at the 
at the lower and upper limit of the 
range. 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
statistical tests (vs. quadratic 
regression). 
F-test of the variances at the 
at the lower and upper limit of the 
range. 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
statistical tests (vs. quadratic 
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Non-linear 
100 % -method (area 
normalization for 
impurities): 
Continuous function 
For main peak: linear 
function 
Non-significant 
ordinate intercept 
Homogenity of 
variances3 
For impurities: linear 
function 
regression). 
Appropriate equation 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
statistical tests (vs. quadratic 
regression). 
Inclusion of zero in confidence 
interval of the ordinate intercept, 
magnitude of the intercept (as 
percent of the signal 100% test 
concentration). 
F-test of the variances at the 
at the lower and upper limit of the 
range. 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
statistical tests (vs. quadratic 
regression). 
May be presumed for limited range (factor 10 '-20). 
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Limits of detection and quantitation 
The limit of detection (LOD) of a technique can be conceived of as the 
smallest concentration, or amount of analyte that can be established as being 
different, at a reasonable statistical confidence level, from a blank (a material similar 
is composition to the sample except that the analyte is absent) [209-211]. One 
common defintion of LOD is the concentration (or quantity) of analyte that produces 
a signal that exceeds the signal observed from a blank by an amount equal to three 
times the standard deviation for the measurement on the blank [211, 212]. At analyte 
concentrations at or near the LOD, the precision of the measured data is usually 
poor. Thus, it is inadvisable to attempt to quantify the analyte unless its 
concentration is well above the LOD. 
A limit of quantitation (LOQ), defined as the analyte concentration for which 
the signal exceeds that for a realistic analytical blank by 10 times the standard 
deviation, is often specified as the smallest analyte concentration that one should 
attempt to quantify [211,212]. Several approaches have been given in the ICH 
guidelines to determine the detection and quantitation limit (Table 1.7.). 
Range of analytical method 
The range of analytical method is the concentration interval over which 
acceptable accuracy, linearity, and precision are obtained. In practice, the range is 
determined using data from the linearity and accuracy studies. Fig. 1.3 illustrates the 
definition of the dynamic range of an analytical method, which extends from the 
lowest concentration at which quantitative measurements can be made (limit of 
quantitation, or LOQ) to the concentration at which the calibration curve departs 
from linearity (limit of linearity, or LOL). To be very useful, an analytical method 
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Table 1.7 
Approaches for determining the limits of detection and quantitation [200]a 
Approach Detection limit Quantitation limit 
Visual evaluation Minimum level detectable Minimum level quantifiable 
Signal-to-noise 3:1 or 2:1 10: 1 
Standard deviation of 3.3 x S0/b 10.0 xS„/b 
the response (S0)b and the 
slope (b) 
a
 verification with a suitable number of samples. 
Standard deviation of the blank, residual standard deviation of the calibration line, 
or standard deviation of the intercept. 
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VI 
a 
o 
C 
E 
s 
Concentration 
Fig. 1.3. Useful range of an analytical method: LOQ = Limit of 
quantitation and LOL = Limit of linear response. 
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should have a dynamic range of at least two orders of magnitude. Some methods 
have applicable concentration range of five to six orders of magnitude. 
Robustness/ ruggedness 
Robustness testing is now a days best known and most widely applied in the 
pharmaceutical world because of the strict regulations in that domain set by 
regulatory authorities which require extensively validated methods. International 
Conference on Harmonisation of Technical Requirements for Human Use (ICH) 
[214] defines "the robustness/ ruggedness of an analytical procedure as a measure of 
its capacity to remain unaffected by small, but deliberate variations in method 
parameters and provides an indication of its reliability during normal usage [215]. 
The term ruggedness is frequently used as a synonym [216-219]. The ICH 
guidelines [215] also recommend that "one consequence of the evaluation of 
robustness should be that a series of system suitability parameters (e.g. resolution 
test) is established to ensure that the validity of the analytical procedure is 
maintained whenever used". Several definitions for robustness or ruggedness exist 
which are, however, all closely related [220-223]. 
The Dutch pharmacists guidelines [220], the ICH guidelines [224] as well as 
some authors working in bio-analysis [225] consider robustness a method validation 
topic performed during the development and optimization phase of a method, while 
others [226] consider it as belonging to the development of the analytical procedure. 
Therefore, the robustness test can be viewed as a part of method validation 
that is performed at the end of the method development or at the beginning of the 
validation procedure. 
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Equivalence testing 
An important property of an analytical method is that it should be free from 
the systematic error (bias). Determining bias involve analyzing one or more standard 
reference materials whose analyte concentration is known. However, random errors 
make it unlikely that the measured amount will equal the known amount even when 
no systematic errors are present. In order to decide whether the difference between 
the observed and standard values can be accounted for by random variation, a 
statistical test known as a significance test is used in the interpretation of analytical 
data. 
Student's t-test 
Here comparison is made between two sets of replicate measurements made 
by two different methods, one is the test method while other is accepted (reference 
method). A statistical t-value is calculated using the relation: 
xi - X 2 | nxn2 
Sp \n,+n2 
where 
x, = Mean from the test method 
x2 = Mean from the accepted (reference) method 
ni and n2 = Number of measurements. 
Sp = Pooled standard deviation of the individual measurements of two sets is 
given by 
= |(i»,--i)s,2 + (7i,-i)sr 
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The calculated t-value is compared with a tabulated value for the given 
number of tests at the desired confidence level. If tcai> ttab then there is a significant 
difference between the results obtained by the two methods at the given confidence 
level. But if, tcai < ttab then there is no significant difference between the methods 
compared. 
F-test 
This test allows comparison of the variance i.e. the square of the standard 
deviation of the two methods (the new method and the accepted reference method) 
and indicates whether there is a significant difference between the two methods or 
not. If Si and S2 are the standard deviations, then 
where 
S{ > S22 
If Fcai> Ftab at the selected confidence level, then there is a significant 
difference between the variances of the two methods. 
Interval hypothesis 
For pharmaceutical analysis, a bias of ± 2.0 % is acceptable [227] and can be 
calculated statistically [228]. For example, the test method (method 2) is considered 
acceptable if its true mean is within ± 2.0 % of that of the reference method 
(method 1). This can be written as 
0.98 < fi2/fn < 1.02 
which can be generalized to 
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where 6L and 9u represent the lower and the upper acceptance limits, respectively, 
when u.2 is expressed as a portion of the reference method \i\. Statistically, 6Land Ou 
can be calculated from the relation: 
d2 [x2 - S\tJ Inx)+ 0(-2*, x2) + (x22 - S2ptJ / /i2 )= 0 
The lower limit (9L) and the upper limit (0u) of the confidence interval are obtained 
as: 
0L=-
%=• 
-b-jb2-4ac 
2a 
-b + 4b2 -Aac 
where 
_ 2
 ^p hab 
a = x\ — 
nx 
b - -2x1X2 
C 2 2 
~
2
 ^p hub 
C = X2 - — 
where xi and X2 are the estimates of \x\ and p.2 based on ni and n2 measurements 
respectively. Sp is an estimate of the pooled S of the measurements. /tab is the 
tabulated one sided /-value, with ni + n2 - 2 degrees of freedom at the specified level 
of significance. 
Testing for outliers 
Frequently, when a series of replicate measurements of same quantity are 
made, one of the results will appear too different markedly from the other. There is 
then a great temptation to discard this "outlier" before calculating the mean and the 
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standard deviation of the data or applying statistical tests to compare the data with 
other measurements. The best-known method used for this purpose is Dixon's Q 
test. 
_ | Suspected value - Nearest value | 
(Largest value-Smallest value) 
If QcaK" Qtab at a given confidence level, then the outlier can be rejected. 
Statistical treatment of calibration data 
The quality control sample sequence is carefully monitored for systematic 
errors. For each standard curve, the slope, intercept, variance, correlation coefficient 
and the interpolated calibrated concentrations are reported. 
Acceptance of the assay results are determined by monitoring the quality 
control results. If the interpolated concentrations are within the control charts 
confidence limits, established during the method validation, the data are considered 
valid. Upon completing a study proper and accepting the analytical runs, the quality 
control results are incorporated into their respective data basis to update their 
confidence limits. 
Correlation and regression 
When using instrumental methods it is often necessary to carry out a 
calibration procedure by using a series of samples (standards) each having a known 
concentration of the analyte. Two statistical procedures should be applied to a 
calibration curve: 
• test whether the graph is linear or in the form of a curve 
• find the best straight line (or curve) through the data points 
Linearity is often tested by the correlation coefficient, 'r', which can be 
calculated for a calibration curve to ascertain the degree of correlation between the 
measured instrumental variables and the sample concentration. 
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r= Vx^-nxy 
I —2 — 2 
^(Ixf - nx )(lyf - ny ) 
= nLx,yt - Lx,Xy,. 
where 
x= Mean of all the values of x, 
y = Mean of all the values of yt 
n = Number of data points 
The maximum value of r is 1. When this occurs there is exact correlation 
between the two variables (x and y). When the value of r is zero (xy = 0), there is 
complete independence of the variables. The minimum value of r is -1 , indicates that 
the assumed dependence is opposite to what exists. As a general rule, 0.90 < r < 0.95 
indicates a fair curve, 0.95 < r < 0.99 as a good curve, and r > 0.99 includes 
excellent linearity. 
Linear least squares 
Once a linear relationship has been shown to a high probability by the value of 
the correlation coefficient, r, then the best straight line through the data points has to 
be evaluated by linear regression (the method of least square). The equation of the 
straight line is A= a + b C where A is usually the measured variable that is 
absorbance, plotted as a function of C that is the concentrations of the standards in a 
spectrophotometric calibration. To obtain the regression line A on C, the slope b of 
the line and the intercept 'a' on the Y-axis are given by following equations. 
b^Zxiyi-[(£x£yi)ln] 
a-y-bx 
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Errors in the slope and the intercept 
where y values are obtained from calculated regression line for given values of x; 
once the value S0 has been obtained, both the standard deviations of the slope Sb and 
the intercept Sa can be obtained from the following equations 
sb=s^nx.-xf 
Sa=S0^Zxl2/n?:(xl-x')2 
Error in the estimation of concentration 
c _ S0 , i (y ~yf 
n b2l(x-xf 
1/2 
where xand y are the average concentration and absorbance values, respectively for_ 
n standard solutions. 
Confidence limit 
The confidence limit defined by the experiment means ' x' of 'n' replicate 
measurements and the standard deviation (s) within the range where the true value 
falls is given by 
C.L. for u,= x±-j=r 
•sjn 
where 
u- = true mean 
t = statistical factor that depends on the number of degrees of freedom and 
the confidence level desired. 
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DRUGS 
Infections and 
Infestations 
Central Nervous 
System 
Endocrine 
System 
Antibiotics and Antitubercular Drugs Antifungals 
Antibacterials 
Genitourinary 
System 
Cardiovascular 
System 
H2 receptor antagonists 
Cimetidine 
Ranitidine 
Famotidine 
Roxatidine 
GajStrointestinal System Nutrition 
Antiulcer Laxatives Antihepatic 
Proton pump inhibitors 
Pantoprazole 
Lansoprazole 
Esomeprazole magnesium 
Rabeprazole sodium 
Fig. 1.4. Classification of drugs based on pharmacological action on human organs. 
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drugs and ulcers due to the rare Zollinger-Ellison syndrome. It appears that exposure 
of the involved tissue to acid is essential to the development of clinical symptoms in 
most instances of these diseases. Control of gastric acidity is, therefore, a 
cornerstone of therapy in these disorders, even though these approaches may not 
address the fundamental pathophysiological process. This thesis deals with 
quantitative analysis of certain antiulcer drugs with special reference to proton pump 
inhibitors (pantoprazole, lansoprazole, esomeprazole magnesium, rabeprazole 
sodium) in pharmaceutical formulations. 
PANTOPRAZOLE (C16H15F2N3O4S) 
Pantoprazole, 5 -difluoromethoxybenzimidazole-2-yl 3,4-dimethoxy-2~ 
pyridylmethyl sulphoxide (CAS: 102625-70-7; MW: 383.4) is an irreversible 
proton pump (H+/ K+- ATPase) inhibitor (PPI) that decreases acid secretion from 
gastric parietal cells and its major metabolite is pantoprazole sulphone. It is also 
effective in Zollinger-Ellison syndrome and in preventing ulcer rebleeding. Thus 
pantoprazole is a valuable alternate to other PPIs in the treatment of acid related 
disorders. 
Pantoprazole 
LANSOPRAZOLE (C16Hi4F3N302S) 
Lansoprazole is an important proton pump inhibitor that suppresses gastric 
acid secretion by specific inhibition of the gastric H+, K+ ATPase enzyme system at 
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the secretory surface of the gastric parietal cells. It is chemically known as 2-[[[3-
methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl], IH-Benzimidazole 
[CAS: 103577-45-3; MW: 369.36]. The drug is effectively useful in the treatment of 
duodenal ulcer, gastric ulcer, reflux oesophagitis and helicobactor pylori infection. 
In addition to its efficacy in healing or maintenance treatment it may provide more 
effective system relief than other comparator agents. 
Lansoprazole 
ESOMEPRAZOLE MAGNESIUM (C34H36MgN606. 3H20) 
Esomeprazole magnesium is chemically known as 5-methoxy-2-{(S)-[(4-
methoxy-3,5-dimethyl-2-pyridyl) methyl] sulfinyl} benzimidazole magnesium 
trihydrate (CAS: 217087-09-7; MW: 767.2). This is the first proton pump inhibitor 
developed as a single optical isomer for the treatment of acid-related diseases. It has 
the advantages over omeprazole in terms of pharmacokinetic characteristics and acid 
suppression. The drug is used in the management of patients with gastroesophageal 
reflux disease, erosive reflux esophagitis and peptic ulcer. The drug is a weak base 
that is concentrated in the acidic compartment of secretory canaliculus of the parietal 
cell where it undergoes acid-catalysed transformation to a tetracyclic achiral cationic 
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sulphenamide. This then reacts with specific cysteines resulting in the inhibitation of 
the H+ / K+- ATPase enzyme. 
Esomeprazole magnesium 
RABEPRAZOLE SODIUM (CisHaoWaOsS) 
Rabeprazole sodium is chemically known as 2-({[4-(3-methoxy propoxy)-3-
methyl-2-pyridyl] methyl} sulfinyl)-lH-benzimidazole sodium (CAS: 117976-89-3; 
MW: 381.4). It is well-tolerated proton pump inhibitor. It has proven efficacy in 
healing, symptom relief and prevention of relapse peptic ulcers and gastro-
oesophageal reflux disease. It is an important alternative to H2 antagonists and an 
additional treatment option to other proton pump inhibitors in the management of 
acid related disorders. It inhibits the gastric parietal cell proton pump (H+ / K+-
ATPase), dose dependently reducing basal and peptone stimulated acid secretion 
with 20 mg per day providing the optimum antisecretory effect. 
Rabeprazole sodium 
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CHAPTER-
KINETIC SPECTROPHOTOMETRIC ANALYSIS 
OF PANTOPRAZOLE IN COMMERCIAL DOSAGE 
FORMS 
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INTRODUCTION 
Pantoprazole, 5-difluoromethoxybenzimidazole-2-yl 3,4-dimethoxy-2-
pyridylmethyl sulphoxide (CAS: 102625-70-7; MW: 383.4) is an irreversible proton 
pump (H+/ K+- ATPase) inhibitor (PPI) that decreases acid secretion from gastric 
parietal cells; its major metabolite is pantoprazole sulphone [1]. The structural formulae 
are shown in Scheme 2.1. It is also effective in Zollinger-Ellison syndrome and in 
preventing ulcer rebleeding. Thus pantoprazole is a valuable alternate to other PPIs in 
the treatment of acid-related disorders. The drug is officially listed in Martindale The 
Extra Pharmacopoeia [2]. The assay of drug in bulk and dosage forms is not announced 
in any pharmacopoeia and therefore requires much more investigation in order to assure 
the exact quantity of drug in pharmaceutical formulations. A literature survey reveals 
that high performance liquid chromatography [3-5], capillary zone electrophoresis [6], 
and voltammetry [7] have been employed for its quantification. The above-mentioned 
techniques, of course, are sensitive enough but are expensive. Spectrophotometry is the 
technique of choice even today due to its inherent simplicity. It is frequently used in the 
laboratories of the developing countries to overcome a variety of analytical problems. In 
the literature only a few spectrophotometric methods have been reported. Two 
derivative spectrophometric procedures [8,9] have been described for the determination 
of pantoprazole in drug formulations. The drug content in pharmaceutical preparations 
has been determined spectrophotometrically [10] in the visible region based on the 
reaction of drug with Fe(III) to form an orange-coloured chelate, which absorbed 
maximally at 455 nm. The drug forms a ternary complex with eosin and copper, which 
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is a basis for its analysis at 549 nm [11]. The charge transfer complexation reaction 
between the drug and 2,3-dichloro-5,6-dicyano-l,4-benzoquinone or iodine has been 
used to quantify the drug spectrophotometrically [11]. A kinetic spectrophotometric 
method based on the reaction of pantoprazole with l-fluoro 2,4-dinitrobenzene in 
dimethyl sulphoxide medium [12] has been reported; this showed a linear response over 
the concentration range of 10.0 - 20.0 |ig ml"1. 
In this chapter, a kinetic spectrophotometric method for the determination of 
pantoprazole in drug formulations is described. The method is based on the oxidation of 
pantoprazole with Fe(III) in sulphuric acid medium; Fe(III) subsequently reduced to 
Fe(Il), which reacts with potassium ferricyanide to form a Prussian blue product, 
absorbing maximally at 725 nm. The initial-rate method is applied for the determination 
of pantoprazole. The method is optimized and validated as per the guidelines of the 
International Conference on Harmonisation [13]. 
EXPERIMENTAL 
Apparatus 
A Shimadzu uv-visible spectrophotometer (UVmini-1240, Shimadzu 
Corporation, Kyoto, Japan) was used for all absorbance measurements with matched 
quartz cells. 
Reagents and standards 
All chemicals and reagents were of analytical or pharmaceutical grade. 
Pantoprazole was kindly supplied by Concept Pharma. Ltd. (Mumbai, India) and was 
used as the reference standard. A standard solution of pantoprazole (0.1%) was prepared 
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by dissolving 50 mg in 50 ml distilled water. Pharmaceutical formulations of 
pantoprazole such as Pantec-20 (Concept, Mumbai, India) and Pantodac-20 (Zydus 
Cadila, Ahmedabad, India) were purchased from local markets. 
Ammonium ferric sulphate (3.0 x 10"3 M; Fluka Chemie AG, Switzerland) 
solution was prepared by dissolving 144.66 mg of ammonium ferric sulphate in 0.003 
M sulphuric acid. Potassium ferricyanide (2.5 x 10' M; Fluka Chemie AG, 
Switzerland) solution was prepared in distilled water. 
Recommended procedure 
Aliquots of 0.05 - 0.9 ml standard solutions of pantoprazole were pipetted into a 
series of 10.0 ml standard volumetric flasks. To each flask, 1.7 ml of 3.0 x 10~3 M 
ammonium ferric suphate was added, followed by 1.5 ml of 2.5 x 10"3 M potassium 
ferricyanide. Then the mixture was diluted to volume with distilled water at 35±1 C. 
The contents of each flask were mixed well and then immediately transferred to the 
spectrophotometric cell. The increase in absorbance was recorded at 725 nm as a 
function of time for 8.0 min. The initial rate of the reaction (v) at different 
concentrations was obtained from the slope of the initial tangent to the absorbance-time 
curve. The calibration graph was constructed by plotting the initial rate of reaction, v 
versus concentration of pantoprazole (C, u.g ml"). The amount of the drug was 
evaluated either from the calibration graph or from the regression equation. 
Procedure for the determination of pantoprazole in pharmaceutical formulations 
The quality control sample solution containing pantoprazole at a concentration of 
1.0 mg ml"1 was prepared. The contents of 5 tablets of 20 mg strength were obtained by 
gentle peeling of the hard coated shells. The contents of the tablets were put in distilled 
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water and left for 10.0 min for complete dispersion of the drug. Then the solution was 
filtered through a piece of Whatmann No. 42 filter paper (Whatmann International 
Limited, Kent, UK) in a 100 ml standard volumetric flask. The residue was washed well 
with distilled water for complete recovery of the drug and then the mixture was diluted 
up to the mark with distilled water. The assay was completed following the proposed 
procedure for the determination of pantoprazole. 
Procedure for the determination of pantoprazole in synthetic mixtures 
Synthetic mixtures of pantoprazole were prepared by taking various excipients 
commonly used in tablet dosage forms with 800 u.g of pantoprazole in 10 ml standard 
volumetric flask and tested to study the interferences of excipients such as sodium 
stearyl fumarate, magnesium stearate, corn starch, lactose and talc. 
Procedure for reference method [11] 
Aliquots of 0.1 - 0.6 ml of 0.1% pantoprazole were pipetted into a series of 10 
ml standard volumetric flasks. To each flask, 6.0 ml of 0.4% 2,3-dichloro-5,6-dicyano-
1,4-benzoquinone was added and the mixture was diluted to volume with acetonitrile. 
The absorbance was measured against the reagent blank at 457 nm. The amount of the 
drug in a given sample was computed from the calibration graph. 
Validation 
The proposed kinetic method has been validated for specificity, linearity, limit of 
detection, precision, accuracy and recovery. 
Specificity 
The reference standard and quality control samples of pantoprazole were 
subjected to stress conditions of light, heat, acid, base and oxidants. Each stressed 
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sample was measured to determine the content of pantoprazole and the results were 
compared to those for an unstressed time zero reference solution. The reference assay 
value for each unstressed product was evaluated and the contents of degradation in the 
stressed and control samples were estimated relative to this assay value. 
Linearity 
The linearity was evaluated with 10 standard solutions: 5.0, 10.0, 15.0,20.0, 
35.0, 50.0, 60.0, 70.0, 80.0 and 90.0 jig ml'1. The determination was repeated five times 
at each concentration level. 
Limits of detection (LOB) and quantitation (LOQJ 
The limits of detection (LOD) and quantitation (LOQ) for the assay were 
calculated using the equations [14]: 
LOD = 3.3 x So/ b and LOQ = 10 x S0/ b 
where So and b are the standard deviation and the slope of the calibration line. 
Accuracy and precision 
Intra-day precision and accuracy of the proposed method were evaluated by 
replicate analysis (n - 5) of calibration standards at three concentration levels (20.0, 
50.0, and 80.0 u.g ml"1). Inter-day precision and accuracy were determined by assaying 
the calibration standards at the same concentration levels on five consecutive days. 
Precision and accuracy were based on the calculated relative standard deviation (RSD, 
%) and relative error (RE, %) of the found concentration compared to the theoretical 
one, respectively. 
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Recovery studies 
The recovery of pantoprazole from commercial dosage forms was estimated by 
the standard addition method. For this purpose, a volume of 2.0 ml (or 5.0 ml) of 
sample solution was spiked with 2.0, 4.0, 6.0 and 7.0 ml (or 1.0, 2.0, 3.0 and 4.0) of 
reference standard solution (1.0 mg ml"1) in a 100 ml standard volumetric flask and the 
mixture was diluted up to the mark with distilled water. Each level was repeated 5 
times. The nominal value was determined by the proposed procedure. 
Evaluation of bias 
The point and interval hypothesis tests have been performed to compare the 
results of the proposed method with those of the reference method at 95% confidence 
level. The bias was evaluated by an interval hypothesis test based on the mean values of 
the proposed method (method 1) and the reference method (method 2). The test method 
is considered acceptable when its true mean is within ± 2.0 % of that of the reference 
method. This can be written as 
which can be generalized to 
where 0i and 0u are lower and upper acceptance limits, respectively which were 
calculated from the following quadratic equation [15]. 
e
1
^ ~sy in^-e^+^-s2/ in2)=o 
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RESULTS AND DISCUSSION 
Dialkyl/diaryl/alkyl-aryl sulphoxides undergo oxidation with a number of 
oxidants [16,17] to form sulphone derivatives. Pantoprazole is a sulphoxide derivative 
that is oxidized in a similar manner by ammonium ferric sulphate in moderately acidic 
medium to form pantoprazole sulphone [3], and itself reduces to Fe(II). The reduced 
Fe(II) immediately reacts with potassium ferricyanide, resulting in the formation of 
Prussian blue product [18], which absorbs maximally at 725 nm. The absorbance of the 
coloured solution increases with time and hence, a kinetically-based spectrophotometric 
method was elaborated to assay the pantoprazole in pharmaceutical formulations. The 
various experimental parameters affecting the formation of coloured product were 
optimized and used throughout the experiment. 
TLC study of pantoprazole and its oxidized product 
To identify pantoprazole and pantoprazole sulphone, we used thin layer 
chromatography. The reference standard solutions of pantoprazole or of pantoprazole 
sulphone was applied on TLC plates coated with silica gel G (Merck, India) and 
developed in chloroform-methanol (10:0.7 v/v) solvent system. The plates were freed 
from mobile phase, dried and spots were detected in iodine chamber. The R{values were 
0.54 and 0.66 for pantoprazole and pantoprazole sulphone, respectively. The R? value 
(0.66) of the reaction product confirmed the presence of pantoprazole sulphone. 
Optimization of Variables 
The optimum conditions for the proposed method responsible for the formation of 
the blue product were studied and maintained throughout the experiment. 
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Effect of temperature 
The effect of temperature on the initial rate of reaction was studied at 303, 308, 
313 and 318 K. The absorbance-time curves showed that the reaction rate increases with 
increase in temperature. At temperature > 313 K, the linear dynamic range of 
determination decreases. The linear dynamic range, regression equation and correlation 
coefficient obtained at different temperatures are summarized in Table 2.1. The best 
linearity was obtained at 308 K and hence this temperature was selected as an optimum 
temperature for the determination process. 
Effect of ammonium ferric sulphate concentration 
The effect of ammonium ferric sulphate concentration on the initial rate of reaction (v) 
was studied in the range of 2.40 x 10'4 - 6.60 x 10'4 M keeping constant [potassium 
ferricyanide] = 3.75 x 10"4 M and [pantoprazole] = 2.09 x JO"4 M. The initial rate of 
reaction increased with increase in the concentration of ammonium ferric sulphate and 
became constant at 3.90 x 10'4 M, and remained as such up to 6.60 x 10"4 M. The results 
are summarized in Table 2.2. Therefore, a concentration of 5.10 x 10'4 M ammonium 
ferric sulphate was recommended for the determination procedure. 
Effect of potassium ferricyanide concentration 
The effect of potassium ferricyanide concentration on the initial rate of reaction 
(v) was investigated in the range of 2.50 x 10"s -5.00 x 10*4 M. The maximum value of 
the initial rate of reaction was obtained with 2.25 x 10'4 M potassium ferricyanide, after 
which further increase in the concentration of potassium ferricyanide up to 5.00 x 10'4 
M resulted in no change in the initial rate of reaction (Table 2.2). Thus, the 
concentration of 3.75 x 10"4 M potassium ferricyanide was found to be most suitable 
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Table 2.1 
Linear dynamic range, regression equation and correlation coefficient at different 
temperatures 
Temperature 
(K) 
303 
308 
313 
318 
Beer's law range 
Otgml-1) 
10.0-90.0 
« = 9 
5.0 - 90.0 
« = 10 
5.0 - 90.0 
n = 10 
5.0 - 70.0 
w = 8 
Regression equation 
v = -4.615x 10"6 + 
1.548 x \0'5C 
v = 3.467 x 10"6 + 
4.356 x 10"5 C 
v = 2.333 x 10"5 + 
5.606 x 10"5 C 
v = 2.455 x 10'5 + 
6.559 x 10"5 C 
Correlation coefficient 
(r) 
0.9993 
0.9999 
0.9995 
0.9998 
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Table 2.2 
Effect of the concentrations of ammonium ferric sulphate and potassium ferricyanide on 
,-4--the initial rate of reaction at [Pantoprazole] = 2.086 x 10 M 
Ammonium ferric sulphate3 
Concentration, C 
(mol 1"') 
Initial rate of reaction, v 
(mol r1 s-1) 
Potassium ferricyanideb 
Concentration, C 
(mol l'1) 
Initial rate of reaction, v 
(mol T" s"1) 
2.40 x 10" 
3.00 x 10" 
3.60 x 10"' 
3.90 x 10" 
4.50 x 10" 
5.10 x 10" 
6.60 x 10" 
2.98 x 10 
5.95 x 10" 
8.77 x 10" 
1.24 x 10_: 
1.24 x 10 
1.24 x 10 
1.24 x 10': 
-4 
-3 
-3 
2.50 x 10"5 
5.00 x lO"5 
1.00 x 10"4 
1.25 x lO4 
1.75 x lO"4 
2.25 x io4 
2.75 x 10"4 
3.25 x 10"4 
3.75 x 10"4 
5.00 x 10"4 
1.07 x 10' 
2.52 x 10" 
4.27 x 10" 
6.66 x 10" 
1.15 x 10': 
1.24 x 10_: 
1.24 x 10 
1.24 x 10": 
1.24 x 10': 
1.24 x 10 
-4 
-3 
•3 
Keeping constant [Potassium ferricyanide] = 3.75 x 10"*M. 
' Keeping constant [Ammonium ferric sulphate] = 5.10 x 10-4 M. 
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concentration for the determination process. 
Analytical data and method validation 
The oxidation of pantoprazole takes place with Fe(III) in acidic medium, resulting 
in the formation of pantoprazole sulphone; subsequently, reduced Fe(II) reacts with 
potassium ferricyanide to form the blue product. The course of the reaction was 
followed spectrophotometrically at 725 nm. The initial rates of reaction for different 
concentrations of pantoprazole at 308 K were determined from the slopes of the initial 
tangent to the absorbance-time curves (Fig. 2.1); these rates are summarized in Table 
2.3. The kinetic equation for the reaction of pantoprazole with Fe(III) and potassium 
ferricyanide is written as: 
v - — zzkC" Cm C' 
Jt ' Drug^- FeVlI)1- ferricyanide 
Under the optimized experimental conditions, i.e. CFe(iii) ^  5.10 x 10"4 M and Cfemcyanide 
~5L 3.75 x 10"4 M, the reaction became pseudo-zero order with respect to the reagent 
concentrations. 
Therefore, the above equation reduced to v = kxC"} where k\ is the first rate 
constant and n is the order of the reaction. The order with respect to pantoprazole was 
evaluated from the plot of log v versus log C and was found to be 1. 
Hence, the reaction would obey the pseudo-first order condition and thus the 
above equation reduced to v = &,C0n,K . 
A calibration graph was constructed by plotting the initial rate of reaction (o) 
versus the pantoprazole concentration (Q; the graph showed a linear relationship over 
the concentration range of 5.0 - 90.0 u.g ml"1 at 308 K. The regression of initial rate 
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o 1 4 5 
Time (min) 
Fig. 2.1. Absorbance-time curves for the initial rate of reaction of pantoprazole: 
5.10 x 10"4 M ammonium ferric sulphate and 3.75 x 10"4 M potassium ferricyanide 
with (a) 5.0, (b) 10.0, (c) 15.0, (d) 20.0, (e) 35.0, (f) 50.0, (g) 60.0, (h) 70.0, (i) 80.0 
and (j) 90.0 pig ml"1 of pantoprazole. 
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Table 2.3 
Initial rate of reaction for different concentrations of pantoprazole with [Fe(III)J = 5.10 x 
10"* M and [Potassium ferricyanidej = 3.75 x 10"4 M at 308 K 
[Pantoprazole] Initial rate of reaction, v 
(\xg ml"1) (mol T') (mol l'1 s'1) 
5.0 
10.0 
15.0 
20.0 
35.0 
50.0 
60.0 
70.0 
80.0 
90.0 
1.304 xJO'5 
2.608 xlO'5 
3.912 x 10"5 
5.216 x 10'5 
9.128 x 10"5 
1.304 x 10"4 
1.564 x 10"4 
1.825 x 104 
2.087 xlO"4 
2.347 xlO"4 
2.166 xlO"4 
4.416 xlO"4 
6.583 xlO"4 
8.750 xlO"4 
1.520 xlO"3 
2.170 xlO'3 
2.660 xlO'3 
3.050 xlO'3 
3.500 xlO"3 
3.900 xlO"3 
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versus C gave a linear regression equation, v = 3.467 x 10"6 + 4.356 x 10"5 C with 
coefficient of correlation, r - 0.9999. The confidence limits for the slope of the line of 
regression and intercept were computed using the relation b ± tSb and a ± tSa at 95% 
confidence level and were found to be 4.356 x 10'5 + 4.806 x 10"7 and 3.467 x 10"5 ± 
2.519 x 10"5, respectively. The values of confidence limits for slope and intercept 
indicated the high reproducibility of the initial rate method. The limits of detection 
(LOD) and quantitation (LOQ) were found to be 1.46 and 4.43 u.g ml'1, respectively. 
The small value of variance (3.716 * 10"10 u.g ml"') also confirmed the negligible 
scattering of the calibration data points around the line of regression. 
Solution stability and selectivity 
Pantoprazole is stable under neutral to moderately acidic conditions (pH ~ 3.5 -
7.4) [19]. The solution stability of pantoprazole was checked by observing UV spectra 
of pantoprazole for 14 h. The aqueous solution of the drug having Amax at 298 nm 
showed no changes in the absorption spectra of standard and quality control sample 
solutions of drug for at least 14 h, when the solutions were stored at a temperature < 
45°C. To identify pantoprazole and pantoprazole sulphone, we used thin layer 
chromatography. The standard solution, quality control sample solution and oxidized 
product of pantoprazole were applied on TLC plates coated with silica gel and 
developed in chloroform-methanol (10:0.7 v/v) solvent system. The plates were air-
dried and spots were detected in the iodine chamber. In the case of standard and quality 
control sample solutions, a single spot was observed with Rf= 0.54 corresponding to 
pantoprazole, whereas the oxidized product showed one spot with R{ value of 0.66, 
confirming the presence of pantoprazole sulphone. The proposed kinetic method is a 
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selective one, since the major metabolite of pantoprazole i.e. pantoprazole sulphone 
does not interfere in the determination process. 
Robustness 
The robustness of the proposed method was investigated by challenging each 
operational parameter such as: 
• 1.7 ml of 0.003 M ammonium ferric sulphate in 0.003 M H2S04 (± 0.4 ml) 
• 1.5 ml of 0.0025 M potassium ferricyanide (± 0.5 ml) 
• 35°C (308 K) as the working temperature (±1°C) 
Under these conditions quality control sample solutions from two commercial dosage 
forms claiminig 60.0 u.g ml*1 of active pantoprazole were assayed by performing 5 
independent analyses following the proposed kinetic method. The recovery results are 
appreciable with low values of standard deviation and relative standard deviations. 
Accuracy and precision 
The accuracy and precision of the proposed kinetic method were established by 
performing 5 independent analyses of pantoprazole in pure form at three different 
concentration levels (20, 50 and 80 u,g ml"1) by intra-day and inter-day precisions. The 
recovery results with relative standard deviation, standard analytical error and 
confidence limit are summarized in Table 2.4; they confirm that the accuracy and 
precision were acceptable. Thus the proposed method is effective for the estimation of 
pantoprazole. 
The accuracy of the proposed kinetic method was also tested by performing 
recovery experiments through the standard addition method. The recovery was 
evaluated either by dividing the intercept by the slope value of the line of linear 
Table 2.4 
Test of precision (intra and inter day assays) for analyses of pantoprazole 
Proposed methnri ^ 
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b
aMean for 5 independent analyses 
c SAE standard analytical errof — 
^ - o n f i d e n c e , , , ^ ^ ^ ^ ^ 
agrees of freedom (f =
 2.776). 
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regression of the standard addition method or by the extrapolation of the same line of 
best fit (Figs. 2.2 and 2.3, Table 2.5). It is evident from Table 2.5 that the linearity of 
the regression line of the standard addition method was good. The attractive feature of 
the method is its relative freedom from interference by the usual tablet diluents and 
excipients in amounts far in excess of their normal occurrence in pharmaceutical 
preparations. 
Applicability of (he proposed kinetic method 
The proposed kinetic method has been successfully applied to the determination of 
pantoprazole in pharmaceutical preparations. The results obtained by the proposed 
method were compared to those of the reference method [11] using point and interval 
hypothesis tests. The results (Table 2.6) show that the Student's t- and F- values at 95% 
confidence level are less than the theoretical values, which confirmed that there is no 
significant difference between the performance of the proposed kinetic method and the 
reference method. The interval hypothesis test has also confirmed that no significant 
difference exists between the performances of the methods compared, as the true bias of 
all drug samples is < ±2.0 %. 
The performance of the proposed kinetic spectrophotometric method was 
compared with other existing conventional spectrophotometric methods (Table 2.7). It 
is apparent from Table 2.7 that the present procedure requires 4 min only for obtaining 
the initial rate of reaction, which is proportional to the concentration of pantoprazole. 
The reaction of pantoprazole with ammonium ferric sulphate and potassium 
ferricyanide requires 30 min to develop a stable colour, which is mandatory for 
conventional spectrophotometric methods. Thus, the time of analysis is reduced when 
the kinetic 
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Nominal Concentration (^g ml"1) Spiked —— 
Fig. 2.2. Plot for the recovery evaluation of pantec-20 through standard addition 
method: (a) 20 and (b) 50 \xg ml"1. 
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Table 2.5 
Test of accuracy for analysis of pantoprazole in drug formulations by standard addition method 
Formulations 
Pantec-20 
(Concept) 
Pantodac-20 
(Zydus Cadila) 
Concentration (u.g ml' 
Theoretical 
20.0 
50.0 
20.0 
50.0 
Spiked 
0, 20, 40, 60, 70 
0, 10,20,30,40 
0, 20, 40, 60, 70 
0, 10,20,30,40 
') 
Nominal 
20.004 
50.242 
20.357 
50.233 
Coefficients of linear regression equation 
of standard addition 
Intercept slope ra 
8.766* 10"4 
2.180x 10'3 
8.729x 10"4 
2.150x 10"3 
4.383 x 10'5 
4.339x 10'5 
4.365x 10'5 
4.280x 10-5 
0.9999 
0.9994 
0.9998 
0.9998 
Recovery (%) 
100.02 
100.48 
99.99 
100.46 
a
 Coefficient of correlation. 
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Table 2,6 
Analysis of pantoprazole in commercial dosage forms by proposed method and reference method at 95% confidence level 
Formulations Proposed method Reference method Paired t-valueb F-valueb 0LC 9uc 
Recovery RSD3, Recovery RSDa 
(%) (%) (%) (%) 
Pantec-20 99.99 0.10 100.05 0.10 0.114 1.038 0.989 1.009 
(Concept) 
Pantodac-20 100.06 0.10 99.98 0.10 0.279 1.201 0.991 1.011 
(Zydus Cadila) 
"Mean for 5 independent analyses. 
"Theoretical /-value (V= 8) and F-value (v= 4, 4) at 95 % confidence level are 2.306 and 6.39, respectively. 
cIn pharmaceutical analysis, a bias, based on recovery experiments, of ± 2% is acceptable. 
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Table 2.7 
Comparison of the proposed kinetic spectrophotometric method with existing 
conventional spectrophotometric methods for the assay of pantoprazole in 
pharmaceutical formulations 
Reagents A,nm Reaction time Linear 
dynamic 
range 
(nm) Ogml'1) 
RSD Reference 
FeCl3 in ethanol 
2,3-DichIoro-5,6-dicyano-
1,4-benzoquinone in 
acetonitrile 
Iodine in chloroform 
Copper and eosin in 
chloroform 
Potassium ferricyanide and 
ammonium ferric sulphate 
455 30mina t60C 30-300 1.52 10 
457 Immediately at 10-60 0.53 11 
25'C 
359 5 m i n a t 2 5 C 17.7-141.6 1.21 11 
549 25minat70 'c 4.3-25.9 0.81 11 
725 4 min at 35 C 5-90 0.78 This work 
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spectrophotometric procedure was applied. The other conventional 
spectrophotometric methods using FeCb [10] and eosin and copper [11] need longer 
times to record the absorbance, whereas the method utilizing 2,3-dichloro-5,6-
dicyano-l,4-benzoquinone [11] gives a stable colour instantaneously. The drawback 
of these methods is that they employ an organic solvent while the proposed kinetic 
method is carried in an aqueous system. 
CONCLUSIONS 
The proposed kinetic method is a selective one as the drug contains sulphoxide 
group, which preferentially reduces Fe(III) to Fe(II); subsequently Fe(II) reacts with 
potassium ferricyanide to form Prussian blue. In human and animals, pantoprazole is 
metabolized to pantoprazole sulphone, which did not give a positive result with the 
reagents used. This is a remarkable advantage of the method that Fe(III) in the 
presence of potassium ferricyanide selectively reacts with pantoprazole and give 
Prussian blue product. Point and interval hypothesis tests clearly proved that the 
proposed method has acceptable recovery with a bias of less than ± 2%. The method 
is also useful due to its wide linear dynamic range (5.0 - 90.0 |ag ml"1) and high 
tolerance limit for common excipients found in drug formulations. Hence, these 
advantages encourage the application of the proposed kinetic method in routine 
quality control analysis of pantoprazole in industries, research laboratories and 
hospitals. 
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KINETIC SPECTROPHOTOMETRIC 
METHOD FOR THE DETERMINATION OF 
LANSOPRAZOLE IN PHARMACEUTICAL 
FORMULATIONS 
f 
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INTRODUCTION 
Lansoprazole is an important proton pump inhibitor that suppresses gastric acid 
secretion by specific inhibition of the gastric H+, K+ ATPase enzyme system at the 
secretory surface of the gastric parietal cells [1]. As chemically defined in the 
Martindale, The Extra Pharmacopoeia, [2] it is 2-[[[3-methyl-4-(2,2,2-
trifluoroethoxy)-2-pyridinyl]methyl]sulfmyl], lH-Benzimidazole [103577-45-3; 
M.W. 369.36]. The drug is effectively useful in the treatment of duodenal ulcer, 
gastric ulcer, reflux oesophagitis and helicobactor pylori infection. In addition to its 
efficacy in healing or maintenance treatment it may provide more effective system 
relief than other comparator agents. Owing to the vital importance of the drug the 
development of a sensitive, simple and fast method for the determination of the drug 
is of urgent need. 
The assay of drug is only listed in the monograph of The United States 
Pharmacopoeia, which describes a high performance liquid chromatographic method 
[3]. Lansoprazole has been determined in pharmaceutical preparations using high 
performance liquid chromatography [4-6], high performance thin layer 
chromatography [7,8], capillary electrophoresis [9], flow injection analysis [10] and 
electroanalytical methods [11,12]. The spectrophotometric methods are the 
instrumental method of choice and have practical and significant advantages over 
other methods. In the literature few spectrophotometric methods have been reported 
[13,14] for the quantification of the cited drug. Moustafa has reported [15] three 
spectrophotometric methods. First two methods are based on the charge transfer 
complexation reaction of the drug with 2,3-dichloro 5,6-dicyano 1,4-benzoquinone 
and iodine. Third method involves the formation of a ternary complex of the drug 
with eosin and Cu (II), which absorbs maximally at 549 nm. Lansoprazole forms 
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ion-pair complex with bromocresol green [16], which was extracted into organic 
solvent for quantitative determination at 420 nm. The spectrophotometric procedures 
for its determination in commercial dosage forms have also been discussed based on 
the reaction with p-dimethylaminobenzaldehyde [17], folin-ciocaltaeu's phenol 
reagent [18] and vanillin [19]. 
The literature is still lacking a kinetic spectrophotometric method for the 
determination of cited drug. Furthermore some specific advantages in the application 
of kinetic method can be expected such as selectivity due to measurement of the 
evolution of the absorbance with the time of the reaction. 
In this chapter, a kinetically based spectrophotometric method is proposed for 
the determination of lansoprazole in bulk and capsules by measuring the change in 
the absorbance at 610 nm and 530 nm followed by oxidation of drug with alkaline 
KM11O4 at 25 ± 1°C. The proposed methods are validated statistically as accuracy 
and reliability of the analytical results is crucial for ensuring quality, safety and 
efficacy of the pharmaceuticals. 
EXPERIMENTAL 
Apparatus 
A Shimadzu UV-visible spectrophotometer (Model no. 1601, Kyoto, Tokyo, 
Japan) with matched quartz cells was used to measure the absorption spectra and 
Spectronic 20 D+ (Milton Roy Company, USA) for recording the absorbance of the 
solution. 
Reagents 
All reagents used were of analytical and pharmaceutical grade. Potassium 
permanganate, 6.0 x 10"3M (GR Grade, Merck Limited, Mumbai, India) solution 
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should be freshly prepared and its apparent purity was assayed titrimetrically [20]. 
1.0 M Sodium hydroxide (E. Merck, India) solution was prepared in distilled water. 
Test solution 
Lansoprazole (Cipla, India Ltd.), 0.1%(w/v), solution was prepared by 
dissolving 100 mg in 0.5 ml of 0.10M NaOH and then diluted to 100 ml with 
distilled water. Lansoprazole solution was freshly prepared and used within 5 hours. 
Marketed products 
The commercial pharmaceutical preparations of lansoprazole such as Lanzol 
(Cipla Ltd., Mumbai, India), Lansofast (Cadila Healthcare Ltd., Ahemdabad, India), 
Propilan (Glenmark Pharmaceuticals Ltd., Mumbai, India) and Lancid (Brown and 
Burk Pharmaceuticals Ltd., Bangalore, India) were purchased from local drug store. 
Recommended Procedure 
Method A 
Aliquots of 0.1% lansoprazole solution ( 5 - 1 5 0 jug ml-1) were pipetted into a 
series of 10 ml volumetric flask, after that 1.5 ml of 1M NaOH was added followed 
by 2.0 ml of 6.0 x 10"3M potassium permanganate solution and then diluted to 
volume with distilled water. The contents of the flask were mixed well and 
immediately transferred to the spectrophotometric cell. The absorbance was 
recorded as a function of time at 610 tun against the reagent blank prepared 
simultaneously at 25 ± 1 °C. The initial rate of formation of Mn042" at different 
concentration was evaluated from the slope of the tangent to the absorbance-time 
curve. The calibration curve was constructed by plotting initial rate of reaction 
against the final concentration of lansoprazole in ug ml-1. The amount of 
lansoprazole was calculated either from the calibration curve or corresponding 
regression equation. 
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Method B 
Aliquots of 0.1% lansoprazole solution corresponding to 50 - 700 ug were 
transferred into a series of 10 ml volumetric flask. Then 1 ml of 1M NaOH was 
added followed by 0.8 ml of 6.0 * 10~3 M potassium permanganate solution and 
completed the volume with distilled water. The decrease in absorbance of the 
solution was measured as a function of time at 530 nm. The initial rate of 
disappearance of MnO^ was determined from the slope of tangent to the 
absorbance-time curve. The calibration curve was constructed by plotting A A vs. 
lansoprazole concentration. The amount of lansoprazole was calculated either from 
the calibration graph or corresponding regression equation. 
Procedure for determination of Lansoprazole in capsules 
The content of the capsules (enteric coated granules) were accurately weighed 
and finely powdered. The amount of the powder equivalent to 200 mg of 
lansoprazole was dissolved in 50 ml of methanol and allowed to stand for few 
minutes and filtered on Whatmann No.42 filter paper. The filtrate was evaporated to 
dryness and the residue was dissolved in 0.5 ml of 0.1 M NaOH and diluted to 25 ml 
with distilled water. The recovery of lansoprazole was calculated from the 
corresponding linear regression equations or calibration graphs. 
RESULTS AND DISCUSSION 
The absorption spectrum of lansoprazole solution in distilled water shows two 
absorption bands peaking at 197 and 287.5 nm while that of potassium 
permanganate solution in alkaline medium exhibits an absorption band peaking at 
530 nm. The course of the reaction starts on the addition of aqueous alkaline 
potassium permanganate to the solution of lansoprazole resulting in the formation of 
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new band peaking at 610 run (Fig. 3. 1 a, b, c). This band is attributed due to the 
formation of manganate ion in the presence of drug. Thus, the intensity of the green 
coloured solution increases with time owing to the formation of Mn0 4" whereas the 
absorbance of the solution measured at 530 nm decreases as the reaction proceeds 
due to the disappearance of MnO ~. This was used to develop a kinetically based 
spectrophotometric method for the determination of lansoprazole. 
The optimum conditions affecting the formation of manganate ion were studied 
and maintained throughout the experiment. 
The effect of KMn04 concentration on the absorbance was studied in the 
range 1.2 * 10"4- 1.44 x 10~3M (Fig. 3.2) keeping all other experimental parameters 
constant, [lansoprazole] = 100.0 u.g ml"1 and [NaOH] = 0.1M. It can be seen that 
the highest absorbance was obtained at 9.6 x 10"4 M, above this concentration up to 
1.44 x 10"3 M, the absorbance was unchanged. Thus, the adoption of 1.2 x 10"3M 
KMn04 in the final solution proved to be sufficient for the maximum concentration 
of lansoprazole used in the determination process. 
The dependence of NaOH concentration on the maximum absorbance was 
studied in the range 0.02 - 0.2 M. Fig. 3.3 shows that the absorbance increases with 
increasing NaOH concentration and maximum absorbance was obtained with 
0.09M, after that further increase in the concentration of NaOH up to 0.2 M resulted 
in no change in absorbance. Hence, 0.15 M NaOH was recommended for 
determination procedure. 
In method A, under the optimized experimental conditions, the determination 
of lansoprazole was carried out in excess of potassium permanganate and sodium 
hydroxide solutions with respect to the initial concentration of lansoprazole. As a 
result pseudo zero order reaction condition was obtained with respect to their 
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Fig. 3.1. Absorption spectra of (a) 1.0 ml of 2.707 x 10"4 M lansoprazole 
in distilled water (b) 1.0 ml of 4.50 x 10"3 M K M n 0 4 + 1.5 ml of 1.0 M 
NaOH solutions in distilled water and (c) 1.0 ml of 2.707 x 10'3 M 
lansoprazole + 2.0 ml of 6.00 x 10"3 M K M n 0 4 and 1.5 ml of 1.0 M NaOH 
solutions in distilled water. Each set is diluted in 10 ml standard flask 
with distilled water. 
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Fig. 3.2. Effect of the concentration of KMn04 on the absorbance at 610 
nm (100.0 ng ml"1 lansoprazole). 
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Fig. 3.3. Effect of the concentration of NaOH on the absorbance at 610 
-i 
nm (100.0 p.g ml' lansoprazole) 
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concentrations. Therefore, on the basis of kinetic investigation, kinetic equation for 
the oxidation of lansoprazole by KMn04 in alkaline medium is written as: 
rate = k [C]n [KMn04]m [NaOH]1 (1) 
For [KMn04] > 1.20 * 10"3 Mand [NaOH] > 0.15 M 
The equation (1) reduces to: 
rate = k v [ C ] n (2) 
where Ky is the pseudo-order rate constant, C is the concentration of lansoprazole 
and n is the order of reaction. The logarithmic form of equation (2) may be written 
as: 
log (rate) = log Ky + n log C (3) 
The initial rates of reaction were evaluated at different concentrations of 
lansoprazole by measuring the slopes of the initial tangent to the absorbance (at 610 
nm) - time curves during the first 10 min of the reaction (Fig. 3.4) and the values of 
the results are summarized in Table 3.1. The curve of log rate versus log C gave the 
following linear equation: 
log (rate) =1.281+0.998 log C 
with a correlation coefficient (r) of 0.9998. The value of n in the equation confirmed 
that the reaction is first order with respect to lansoprazole and rate constant is 19.1 
s"1. 
The calibration curve was prepared by plotting initial rate versus concentration 
of lansoprazole and found to be linear over the concentration range of 5 - 150 jag 
ml"1. The regression analysis of calibration data yielded the following regression 
equation: 
rate =-3.915 x 10"6 +5.271 x 10~5C 
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Time (min) 
Fig. 3.4. Absorbance (at 610 nm)-time curves for the first 10 min of the 
reaction between lansoprazole and KMn04 in distilled water: 2.0 ml of 
0.006 M KMn0 4 and lansoprazole: (a) 5, (b) 10, (c) 20, (d) 40, (e) 60, (f) 
80, (g) 100, (h) 120 and (i) 150 ng ml1 . Each set is diluted in 10 ml 
standard flask with doubly distilled water. 
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Table 3.1 
Initial rate of reaction (formation of Mn(V") at different concentration of lansoprazole 
C,[Drug] 
mol L'1 
logC Initial rate of reaction, v log v 
mol T1 s"1 
1.353 xi(T 
2.707 x 10"5 
5.414 x 10-5 
1.083 x 10"4 
1.624 x 10-4 
2.166 x 10"4 
2.707 x 10"4 
3.248 x 10-4 
4.061 xlO'4 
-4.868 
-4.567 
-4.266 
-3.965 
-3.789 
-3.664 
-3.567 
-3.488 
-3.391 
2.583 x lO"4 
5.500 x 10'4 
1.055 x 10"3 
2.083 x 10"3 
3.166 x 10"3 
4.166 x 10"3 
5.300 x 10'3 
6.283 x 10"3 
7.933 x lO'3 
-3.587 
-3.259 
-2.976 
-2.681 
-2.499 
-2.380 
-2.275 
-2.201 
-2.100 
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(n =9, ± rSa = 4.279 x 10-5, ± tSb = 5.285 x 10"4 at 95% confidence level) with 
coefficient of correlation, r = 0.9999. The variance was calculated [21] using 
statistical treatment of calibration data at nine concentration levels and found to be 
9.80 x 10"10 pg ml"1. The low value of variance speaks the negligible scattering of 
the experimental data points around the line of regression. 
In method B, the oxidation of lansoprazole by potassium permanganate in 
alkaline medium was followed spectrophotometrically by measuring the decrease in 
absorbance at 530 nm against a reagent blank prepared similarly except drug. The 
absorbance-time curves are shown in Fig. 3.5. The difference between the 
absorbance obtained at 2 min and the absorbance at 4, 6, 8 and 10 min was plotted 
against the concentration of lansoprazole and the corresponding linear regression 
with coefficient of correlation is summarized in Table 3.2. It is clear from the table 
that the most acceptable linearity was obtained at A2 - Ag, therefore, the quantitative 
analyses of lansoprazole in each sample was carried out at A2 - Ag. The calibration 
curve was linear in the range of 5 - 70 fig ml"1 of lansoprazole and the corresponding 
regression equation is AA = 1.04 x 10~3 + 1.78 x 10"3 C (n = 8, r = 0.9991, ± rSa = 
3.132 x io~3, ± /SA = 7.457 x 10"5 at 95% confidence level). It was found that the 
variance of this procedure was 3.61 x lO^ngml"1. 
The absolute error (Sx) in the determination of a given concentration of 
lansoprazole has been evaluated [22] using the following equation: 
-1/2 
1 , (y-y)2_ 
n b2^(x,-x)2 x b 
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Fig. 3.5. Absorbance (at 530 nm)-time curves for the first 10 min of the 
reaction between lansoprazole and KMn04 in distilled water: 0.8 ml of 0.006 M 
KMn04 and lansoprazole: (a) 5, (b) 10, (c) 20, (d) 30, (e) 40, (f) 50, (g) 60, and 
(h) 70 \xg ml"1. Each set is diluted in 10 ml standard flask with doubly distilled 
water. 
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Table 3.2 
Calibration equations with coefficient of correlation (r) at A2 - A4, A2 - Ae, A2 - As 
and A2 - Aio for method B 
AA Calibration equation r 
A2-A4 A = -2.300 xl(T4 + 6.731 x 104C 0.9907 
A2-A6 A = 1.980 xl0_3 + 1.210 x 10° C 0.9955 
A2-A8 A= 1.040 xl0_3 + 1.780 x 10'3C 0.9991 
A2-A,0 A = 3.130 xl0"3 + 2.200 x 10"3C 0.9942 
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and was plotted in Figs. 3.6 and 3.7. It is found from the figures that the minimum 
error was obtained when the analysis was done at 65.0 and 35.6 p.g ml-1 using 
methods A and B, respectively. The value of Sx also allows to establish the 
confidence limit at the selected level of significance for the determination of 
unknown concentrations by using the relation, Ci ± tpSx. 
The accuracy and precision of the proposed procedures (Methods A and B) 
was established by measuring the content of lansoprazole at three different 
concentration levels (low, medium and high) within one day and on five consecutive 
days. The intra day and inter day assays were performed by measuring six 
independent analyses at 10.0, 60.0 and 130.0 ug ml"1 concentration levels using 
method A. The same assays (intra and inter day) were too done for method B at 
concentration levels: 10.0, 30.0 and 60.0 ug ml"1 on one day as well as on five 
consecutive days. The results of standard deviation, relative standard deviation and 
mean recoveries obtained by intra day and inter day assays for method A and B are 
acceptable and can be considered to be very satisfactory (Table 3.3). 
As an additional demonstration of accuracy, recovery experiments were 
performed by adding a known amount of lansoprazole to the preanalysed dosage 
forms. The total amount of lansoprazole was determined by proposed methods and 
the results are reported in Table 3.4. It is evident from the table that mean recoveries 
were in the range of 99.48% - 100.38% and 99.31% - 100.18% for methods A and 
B, respectively. 
The proposed methods (A and B) were successfully applied to the 
determination of lansoprazole in capsules. The results of proposed methods were 
compared with those of the reference method [15] using point and interval 
hypothesis tests. Calculated t- and F-values shown in Table 3.5 are less than the 
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Fig. 3.6. Error (Sx) in the determination of lansoprazole with Method A. 
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Table 3.3 
Intra day and inter day assays: test of precision of methods A and B 
Proposed methods 
Method A 
Intra day assay 
Inter day assay 
Method B 
Intra day assay 
Inter day assay 
Amount 
(^mf) 
Taken 
10.0 
60.0 
130.0 
10.0 
60.0 
130.0 
10.0 
30.0 
60.0 
10.0 
30.0 
60.0 
Found ± SDa 
9.90 ±0.17 
59.87 ±0.37 
130.11 ±0.54 
9.91 ±0.10 
60.11 ±0.65 
129.30 ±0.93 
10.03 ±0.10 
29.97 ±0.20 
60.08 ± 0.40 
9.90 ±0.16 
29.98 ±0.19 
59.85 ±0.57 
Recovery 
(%) 
99.05 
99.79 
100.08 
99.15 
100.11 
99.50 
100.31 
99.91 
100.14 
99.02 
99.93 
99.75 
RSD 
(%) 
1.77 
0.63 
0.42 
1.04 
1.00 
0.72 
0.99 
0.67 
0.67 
1.61 
0.66 
0.96 
SAE 
0.069 
0.154 
0.220 
0.042 
0.268 
0.340 
0.020 
0.081 
0.164 
0.065 
0.080 
0.234 
C.L. 
0.177 
0.394 
0.565 
0.107 
0.689 
0.874 
0.051 
0.208 
0.421 
0.167 
0.205 
0.601 
a
 Mean for six independent analyses. 
b
 SAE, standard analytical error. 
CC.L., confidence limit at 95 % confidence level and five degrees of freedom (t = 2.571) 
Table 3.4 
Standard addition method for the determination 
of lansoprazole in commerc 
Formulations 
Lanzol 30 
(Cipla) 
Lancid 30 
(Brown & 
Burk) 
J^lethod_A 
Amount 
Taken Added 
Lansofast30 10.0 
(Cadila) 20.0 
50.0 
Propilan 30 
(Glenmark) 
Found ± SDa 
10.0 10.0 20.02 ±0.28 
20.0 40.0 59.81 ±0.61 
50.0 80.0 130.09 ±0.71 
10.0 20.01 ±0.35 
40.0 60.03 ± 0.37 
80.0 129.74 ±0.49 
10.0 10.0 19.90 ±0.27 
20.0 40.0 60.08 ±0.31 
50.0 80.0 129.33 ± 0.92 
10.0 10.0 20.00 ±0.29 
20.0 40.0 59.86 ±0.25 
50.0 80.0 130.50 ±0.83 
Recovery RSD 
(%) 
100.11 
99.68 
100.07 
100.01 
100.05 
99.80 
99.53 
100.14 
99.48 
100.02 
99.76 
100.38 
1.43 
1.02 
0.54 
0.54 
0.61 
1.11 
1.35 
0.51 
0.71 
1.49 
0.42 
0.64 
SAE 
0.117 
0.250 
0.289 
0.290 
0.151 
0.591 
0.110 
0.126 
0.378 
0.122 
0.104 
0.338 
aMean for six independent analyses. 
I l l 
capsules 
Methi 
Amoi 
Ogm 
Taken 
10.0 
20.0 
30.0 
10.0 
20.0 
30.0 
10.0 
20.0 
30.0 
10.0 
20.0 
30.0 
odB 
int 
I/1) 
i Adde* 
10.0 
20.0 
30.0 
10.0 
20.0 
30.0 
10.0 
20.0 
30.0 
10.0 
20.0 
30.0 
i Found ± SDa 
20.03 ± 0.35 
39.94 ± 0.29 
59.71 ±0.59 
19.87 ±0.28 
39.95 ± 0.34 
60.11 ±0.29 
19.86 ±0.27 
39.93 ± 0.32 
59.82 ±0.57 
19.99 ±0.28 
39.94 ±0.31 
60.08 ±0.41 
Recover} 
(%) 
100.18 
99.85 
99.51 
99.35 
99.88 
100.18 
99.31 
99.82 
99.71 
99.95 
99.83 
100.14 
f RSD 
(%) 
1.78 
0.75 
1.00 
1.49 
0.86 
0.49 
1.40 
0.78 
0.96 
1.40 
0.78 
0.67 
SAE 
0.145 
0.121 
0.244 
0.114 
0.140 
0.120 
0.111 
0.128 
0.235 
0.114 
0.128 
0.164 
Table 3.5 
Point and interval hypothesis tests: comparison of the proposed methods with the reference method at 95% confidence level 
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Formulations Method A Method B Reference method 
Recovery RSDa 
(%) (%) 
t-
value value 
F- 6LC 6uc Recovery RSDa t- F- 6LC 
v a l u e b v a l u e b 
0uc Recovery 
(%) 
99.76 
100.06 
99.81 
99.91 
RSDa 
(%) 
0.55 
0.62 
0.64 
0.48 
/ 
Lanzol 30 
(Cipla) 
Lansofast 30 
(Cadila) 
Propilan 30 
(Glenmark) 
Lane id 30 
(Brown & 
Burk) 
99.86 0.46 0.35 1.20 0.995 1.006 99.98 0.65 0.65 1.19 0.995 1.008 
99.76 0.47 0.95 1.29 0.991 1.002 99.91 0.79 0.37 1.28 0.991 1.005 
100.09 0.54 0.81 1.18 0.996 1.009 100.11 0.42 0.97 1.55 0.997 1.008 
100.19 0.51 0.97 1.03 0.997 1.007 99.78 0.61 0.39 1.26 0.992 1.004 
aMean for six independent analyses. 
bTheoretical t-value (y= 10) and F-value (y= 5, 5) at 95 % confidence level are 2.228 and 5.05, respectively. 
c
 In pharmaceutical analysis, a bias, based on recovery experiments, of ±2% ( 6 L = 0.98 and 9u = 1 -02) is acceptable. 
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theoretical ones [23], confirming accuracy and precision at 95% confidence level. 
The interval hypothesis test [24] has also confirmed that true bias of all samples is 
smaller than + 2% at 95% confidence level, since the acceptable interval is within BL 
= 0.98 and 9u = 1.02. 
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CHAPTER 
SPECTROPHOTOMETRIC 
DETERMINATION OF ESOMEPRAZOLE 
MAGNESIUM IN COMMERCIAL TABLETS 
USING 5-SULPHOSALICYLIC ACID AND 
N-BROMOSUCCINIMIDE 
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INTRODUCTION 
Esomeprazole magnesium is chemically known as 5-mefhoxy-2- {(S)-[(4-
methoxy-3, 5-dimethyl-2-pyridyl) methyl] sulfinyl} benzimidazole magnesium 
trihydrate [1,2]. This is the first proton pump inhibitor developed as a single optical 
isomer for the treatment of acid-related diseases. It has the advantages over 
omeprazole in terms of pharmacokinetic characteristics and acid suppression. The 
drug is used in the management of patients with gastroesophageal reflux disease, 
erosive reflux esophagitis and peptic ulcer. The drug is a weak base that is 
concentrated in the acidic compartment of secretory canaliculus of the parietal cell 
where it undergoes acid-catalysed transformation to a tetracyclic achiral cationic 
sulphenamide. This then reacts with specific cysteines resulting in the inhibitation of 
the H+ / K+- ATPase enzyme [3]. The drug is officially listed in Martindale The 
Extra Pharmacopoeia [1]. As far as we are aware that the assay of drug in bulk and 
dosage forms is not cited in any pharmacopoeia (USP or BP or Ph Eur or IP) and 
literature is also not available for its determination. Therefore, there is an urgent 
need for the development of simple, sensitive and accurate methods for the 
determination of esomeprazole magnesium in pharmaceutical products. 
This chapter describes two rapid, simple, sensitive and economical 
spectrophotometeric methods for the determination of esomeprazole magnesium in 
commercial dosage forms. Method A is based on the reaction of esomeprazole 
magnesium with 5 sulphosalicylic acid in methanol leading to the formation of a 
yellow coloured complex which absorbs maximally at 365 nm, Method B utilizes 
the reaction of drug with N-bromosuccinimide in acetone-chloroform medium 
resulting in the formation of yellow coloured a-bromo derivative of the drug. The 
absorption spectrum shows a band peaking at 380 nm. The proposed methods are 
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validated as per the guidelines of International Conference on Harmonisation (USA) 
[4]-
EXPERIMENTAL 
Apparatus 
All absorbance measurements were made on a spectronic 20D+ 
spectrophotometer (Milton Roy Company, USA) with 1cm matched glass cells. The 
absorption spectra were recorded on a shimadzu uv-visible spectrophotometer (UV-
1240, Shimadzu Corporation, Kyoto, Japan) with matched quartz cells. 
Material and reagents 
All chemicals and reagents were of analytical grade. The reference standard of 
esomeprazole magnesium (Batch No. BEO-0840009) was kindly provided by 
Torrent Pharmaceuticals Ltd., Ahmedabad, India. The commercial dosage forms of 
esomeprazole magnesium such as Nexpro-20 (Torrent Pharmaceuticals Ltd. 
Ahmdabad, India), Raciper-20 (Ranbaxy Laboratories Ltd., New Delhi, India) and 
Esoz-20 (Glenmark pharmaceuticals Ltd. Mumbai, India) were obtained from local 
drug stores. 5-sulphosalicylic acid (Qualigens Fine Chem. Ltd., Mumbai, India) was 
prepared as 1.97><10"3 M solution in methanol. N-bromosuccinimide solution (s.d. 
fine-chem. Ltd., Mumbai, India) was prepared as 2.25xlO"2 M in acetone. 
Standard solutions 
• esomeprazole magnesium (0.2 mg ml"1) solution was prepared in methanol. 
• esomeprazole magnesium (0.5 mg ml"1) solution was prepared in chloroform. 
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Procedure for the determination of esomeprazole magnesium 
Method A 
Aliquots (0.05 - 1.2) ml of standard solution of esomeprazole magnesium (0.2 
mg ml"1) were mixed with 1.2 ml of 1.97 * 10"3 M 5-sulfosaicylic acid into a series 
of conical flasks and then heated at 50 ± 1°C for 5 min. The contents of the mixture 
were transferred into 5 ml standard volumetric flask and then diluted up to volume 
with methanol. The absorbance was recorded at 365 nm within the stability time of 5 
h against the reagent blank prepared simultaneously except the drug. The amount of 
the drug in the given sample can be estimated either from calibration graph or 
corresponding regression equation. 
Method B 
The volumes (0.1 - 1.0 ml) of standard solution of esomeprazole magnesium 
(0.5 mg ml"1) were transferred into a series of conical flasks followed by 2.2 ml of 
2.25 x 10"2 M N-bromosuccinimide and warmed at 35 ± 1°C for 12 min. After 
cooling at room temperature (25 ± 1°C), the contents of each conical flask were 
transferred to 5 ml standard volumetric flask and then diluted up to the mark with 
acetone. The absorbance was measured at 380 nm against the reagent blank prepared 
simultaneously omitting esomeprazole magnesium. The colour of the complex was 
stable for at least 1 h. The concentration of the drug was calculated either from 
calibration curve or corresponding regression equation. 
Procedure for the assay of esomeprazole magnesium in pharmaceutical 
formulations 
Ten and twenty-five tablets of 20 mg strength of esomeprazole magnesium 
were taken separately in methanol and chloroform, for methods A and B, 
respectively and left for 10 min for complete dispersion of the drug. The methanol 
and chloroform extracts were filtered through Whatmann No. 42 filter paper 
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(Whatmann International Limited, Kent, UK) in 100 ml volumetric flasks, 
separately. The residues were washed well with 5 * 10 ml portion of methanol and 
chloroform, as the case may be, for complete recovery of the drug and finally diluted 
to volume appropriate solvent. The amount of the drug was determined following 
the proposed procedures. 
Procedure for the reference method 
Aliquots of 0.05 - 1.0 ml of standard solution of esomeprazole magnesium 
(0.2 mg ml"1) were pipetted into a series of 10 ml volumetric flasks and diluting to 
volume with chloroform. The absorbance was measured at 301.5 nm against the 
solvent blank. The amount of the drug in the given sample was computed from the 
calibration graph. 
Determination of validation parameters 
The proposed methods have been validated for specificity and selectivity, 
linearity, accuracy and precision, limits of detection and quantitation, and recovery. 
Solution stability 
The solution stability of pure drug and quality control samples was ascertained 
by observing UV-visible spectra and spots on TLC plates for several days at room 
temperature. The thin layer chromatography was performed using TLC plates coated 
with silica gel G (Merck Limited, Mumbai, India) and developed in 
dichloromethane-methanol-2.67 M ammonia (5:0.3:2 v/v/v) solvent system. Then 
the TLC plates were freed from mobile phase, dried and spots were detected in 
iodine chamber. 
Specificity and selectivity 
The specificity and selectivity of the proposed methods was evaluated by 
determining the concentration of esomeprazole magnesium in the presence of 
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excipients such as glyceryl monostearates, hydroxyl propyl cellulose, magnesium 
stearate, sugar spheres, talc and triethyl citrate commonly found in tablet 
formulations of the cited drug. The content of the drug was also determined in the 
presence of varying amounts of oxidants such as potassium persulfate, ammonium 
molybdate, sodium metavanadate, and chloramine T. 
Linearity 
The linearity of the proposed methods was evaluated at the following 
concentration levels: 2, 4, 8, 16, 20, 24, 36, 40, 44 and 48 \xg ml'1 for Method A and 
10, 20, 30, 40, 50, 70, 90 and 100 ug ml*1 for Method B. Each concentration level 
was repeated five times. 
Accuracy and precision 
The accuracy and precision of the proposed methods were ascertained at three 
concentration levels: 8, 24 and 48 ug ml"1 for method A and 10, 50 and 100 ug 
ml" for method B. Five sample solutions of each concentration were analyzed within 
one day (within day or intra day precision) and in five consecutive days (between 
day or inter day precision). 
Recovery experiments 
The recovery studies were carried out by standard addition technique. In this 
technique, 4.0 ml (or 3.0 ml) of 0.2 mg ml"1 solution (or 0.5 mg ml"1) esomeprazole 
magnesium was mixed separately with 4.0 and 8.0 ml (or 3.0 and 6.0 ml) of 0.2 mg 
ml" (or 0.5 mg ml") reference esomeprazole magnesium in 50 ml standard 
volumetric flask and diluted to the volume with methanol (or acetone). The total 
amount of esomeprazole magnesium was determined by the proposed procedures. 
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Limits of detection (LOD) and quantitation (LOQ) 
The limits of detection and quantitation [5] were calculated using the relations: 
LOD = 3.3 x So / b and LOQ = 10 x So / b where S0 and b are the standard deviation 
and the slope of the calibration line, respectively. 
Ruggedness and robustness 
The ruggedness of proposed methods was ascertained using two different 
spectrophotometers (spectronic 20D+ and shimadzu uv-visible spectrophotometers). 
The robustness of methods A and B was evaluated by observing the influence of 
small variations of experimental variables i.e. concentration of reagents, reaction 
temperature and heating time. 
Evaluation of statistical equivalence testing 
The statistical equivalence testing has been evaluated by means of point and 
interval hypothesis tests [6]. Interval hypothesis test, the test method is compared 
with a reference method and considered to be acceptable if the mean recovery is 
within ± 2.0 % of that of the reference method [7]. This can be written as: 0.98 <jU21 
/x\ < 1.02 where /u\ and /U2 are the population means of the reference and test 
methods, respectively. This can be generalized in a simpler form as: 0L <//21 H\ < % 
where 0L and 0u are the lower and upper acceptance limits, respectively. The limits 
of this confidence interval are obtained from the following quadratic equation: 
#H?-S2ptJ /«,)+0(-2^) + £F -S\tJ /«2)=0 
RESULTS AND DISCUSSION 
The methanolic solutions of esomeprazole magnesium and 5-sulphosalicylic 
acid were found to absorb maximally at 301.5 and 215 ran, respectively. 
Esomeprazole magnesium was allowed to react with 5-sulphosalicylic acid resulting 
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in the formation of yellow coloured product peaking at 365 nm (Fig. 4.1). The 
literature survey revealed that magnesium is capable of forming coloured mixed 
ligand complexes with 4,5-dibromophenyl fluorone and cetyltrimethylammonium 
bromide [8], o-[(l,8-hidroxy-3,6-disulpho-2-naphthyl) azo] benzene arsonic acid 
and [ethylene bis(oxyethylenenitrilo)] tetracetic acid [9], nitrilotriacetate and 5-
nitrosalicylic acid [10]. In the similar manner, magnesium bound esomeprazole as a 
drug reacts with 5-sulphosalicylic acid in methanol to form a yellow coloured 
complex which absorbed maximally at 365 nm. 
The composition of the complex (drug-Mg (II)-5-sulphosalicylic acid) was 
determined by mole ratio method [11]. The results are shown in Fig. 4.2, which 
indicated the esomeprazole magnesium-5-sulphosalicylic acid ratio of 1:4. On the 
basis of our experimental findings and literature background, the reaction sequence 
is shown in Scheme 4.1. 
Esomeprazole magnesium was found to react with N-bromosuccinimide in 
acetone, which yielded a product showing a new characteristic band peaking at 380 
nm (Fig. 4.3). It was reported that N-bromosuccinimide is a brominating agent 
useful in the a- bromination of sulphoxide derivative [12]. Esomeprazole 
magnesium is a base consisting of a-carbon as a prochiral center adjacent to the 
sulphoxide undergoes reaction with N-bromosuccinimide to form yellow a-
bromosulphoxide derivative of the drug. The reaction product absorbed maximally 
at 380 nm. The mole ratio method was used to evaluate the composition of product 
and the results are shown in Fig. 4.4. As can be seen from the figure that the 
combining molar ratio between esomeprazole magnesium and N-bromosuccinimide 
is 1:2. On this basis, the reaction sequence is given in Scheme 4.2. 
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Fig. 4.1. Absorption spectra of (a) 5.213 xlO"5 M (40.0 ug ml"1) esomeprazole 
magnesium (b) 1.968xl0"3 M 5-sulphosalicylic acid, and (c) 5.213 xlO"5 M (40.0 
ug ml"1) esomeprazole magnesium with 3.933 xlO"4 M 5-sulphosalicylic acid in 
methanol. 
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Mole ratio (5-sulphosalicylic acid/ esomeprazole magnesium) 
Fig. 4.2. Mole ratio plot for stoichiometric ratio between esomeprazole 
magnesium and 5-sulphosalicylic acid for method A. 
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Fig. 4.3. Absorption spectra of (a) 5.213 x 10s M (40.0 |ig ml"1) 
esomeprazole magnesium in chloroform (b) 2.247 x 10'2 M N-
bromosuccinimide in acetone and (c) 1.303 x 10"4 M (100.0 jag ml"1) 
esomeprazole magnesium with 9.90 x 10"3 M N-bromosuccinimide in 
acetone. 
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Fig. 4.4. Mole ratio plot for stoichiometric ratio between esomeprazole 
magnesium and N-bromosuccinimide for method B. 
129 
H3CO' 
Mg +2 
-J 2 
Esomeprazole magnesium 
CH2—CO. 
+ 2 | ^NBr 
CH2—CO 
N-bromosuccinimide 
H3CO' 
Acetone 
At 35 °C 
Mg+2
 + , CH 2 —CO x 
CH2—CO 
yellow a-bromosulphoxide derivative of Esomeprazole magnesium Succinimide 
Scheme 4.2 
130 
TLC of esomeprazole magnesium and its reaction products 
The esomeprazole magnesium and its reaction products were analyzed by thin 
layer chromatography. The sample solution of reference drug and the products of 
Method A and B were applied on TLC plates coated with silica gel G (Merck, India) 
as stationary phase. The chromatogram was developed in dichloromethane-
methanol-2.67 M ammonia (5: 0.3: 2 v / v / v) solvent system. The plates were air-
dried and spots were located on placing the plates in iodine chamber. The spots of 
pure drug, reaction products of method A and B were detected with Rf values of 
0.77, 0.54 and 0.67, respectively. 
Optimization of variables 
The optimum conditions for methods A and B have been evaluated by 
studying the reaction as a function of temperature, heating time, concentration of 
reagents, nature of the solvent and the stability of the coloured species. 
Method A 
Effect of temperature 
The effect of temperature on the absorbance of the yellow coloured product 
was studied in the range of 40-5 5°C. It was observed that the rate of reaction 
increases with increase in temperature. At temperature > 50°C, the reaction product 
may decompose and affect the reproducibility of the proposed method. Therefore to 
minimize the time of analysis and for the sake of good results, a temperature of 50°C 
was selected for the determination process. 
Effect of time 
To study the effect of time on the absorbance of the coloured product, 1 ml of 
esomeprazole magnesium (0.2mg ml"1) was mixed with 1.2 ml of 5-sulphosalicylic 
acid (0.5mg ml"1) and kept for different time interval in a water bath maintained at 
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50 ± 1°C. The contents of mixture were diluted to 5 ml with methanol after cooling 
at room temperature (25 ±1°C). It is apparent from the Figure 4.5 that the maximum 
absorbance was obtained at 4 min and remained constant up to 6 min. Therefore, 5 
min of heating at 50 °C was chosen as an optimum value. 
Effect of concentration of 5-sulphosalicylic acid 
The effect of 5-sulphosalicylic acid concentration on the absorbance of the 
coloured product was investigated in the range of 3.93 * 10"5- 5.51 x 10'4 M keeping 
a constant amount of drug (200 p.g). It was found that the absorbance of the coloured 
product increased with increasing concentration of 5-sulphosalicylic acid and 
became constant in the concentration range of 3.93 x 10" - 5.51 x 10"4 M (Fig. 4.6). 
Thus 4.72 x 10"4 M 5-sulphosalicylic acid was adopted as most suitable 
concentration for maximum absorbance. 
Method B 
Effect of temperature 
The effect of temperature on the absorbance of the coloured product was 
investigated over the range 25 - 40°C. It was found that the suitable temperature of 
colour development was 35°C. Therefore, for the sake of good recovery results, the 
optimum temperature of 35°C was selected for the determination procedure. 
Effect of time 
To study the effect of time for the maximum absorbance, 500 jig 
esomeprazole magnesium was mixed with 2.2 ml of 2.25 x 10"2 M N-
bromosuccinimide and allowed to stand at 35 ±1°C. The absorbance was measured at 
380 nm as a function of time. It was apparent from Fig 4.7 that the absorbance 
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Fig. 4.5. Effect of time on the absorbance for Method A. 
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Fig. 4.6. Effect of the concentration of 5-sulphosalicylic acid on the absorbance 
for method A keeping [Esomeprazole magnesium] = 40.0 jj.g ml"1. 
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Fig. 4.7. Effect of time on the absorbance for Method B. 
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remained constant between 10 and 14 min at 35 ± 1°C. Therefore, the reaction time 
of 12 min was chosen for the estimation of esomeprazole magnesium. 
Effect of the concentration of N-bromosuccinimide 
The effect of the concentration of N-bromosuccinimide on the absorbance of 
the coloured product was critically examined in the range of 4.50 x 10"4 - 1.08><10"2 
M. It was found that increasing the concentration of N-bromosuccinimide would 
increase the absorbance of the reaction up to 9.00 x 10"3 M; above this concentration 
absorbance remained constant (Fig 4.8). Therefore, the concentration of 9.90 x 10" 
M N-bromosuccinimide was adopted as an optimum value throughout the 
determination process. 
Solution stability 
It is reported that esomeprazole magnesium has acceptable stability under 
alkaline conditions [13]. The drug is stable in solvents like methanol and 
chloroform. The test and quality control sample solutions showed no change in the 
absorption spectra for three days at room temperature (25±1°C). A single spot was 
resulted in test solution as well as in quality control sample solutions with Rf = 0.77, 
which corresponds to esomeprazole magnesium. 
Specificity and selectivity 
It was found that the common excipients (glyceryl monostearates, hydroxyl 
propyl cellulose, magnesium stearate, sugar spheres, talc and triethyl citrate) did not 
interfere with the proposed procedures. The recovery of drug in presence of oxidants 
such as potassium persulphate, ammonium molybdate, sodium metavanadate and 
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absorbance for method B keeping [esomeprazole magnesium] = 100.0 ng 
ml"1. 
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chloramine T was quite satisfactory by both the procedures. 
Ruggedness and robustness 
The ruggedness of the proposed methods was assessed by analyzing the active 
esomeprazole magnesium in Nexpro-20 tablets at 20 jag ml"1 using two different 
spectrophotometers. The mean % recovery ± RSD was found to vary over the range 
99.98 ±0.32-100.06 ±0.35. 
The robustness of the proposed methods relative to each operational parameter 
was closely monitored. The operational parameters examined were as follows: 
Method A 
• heating temperature, 50 ± 1°C 
« heating time, 5 min (± 1 min) 
• 1.97 x 10"3 M 5-sulphosalicylic acid, 1.2 ml (± 0.2 ml) 
Method B 
• heating temperature, 35 ± 1°C 
• heating time, 12 min (± 2min) 
• 2.25 x 10"2 M N-bromosuccinimide, 2.2 ml (± 0.2 ml) 
The robustness of the proposed methods (A and B) was judged by analyzing 
the active drug contents in tablet formulations (Nexpro 20) under delibrate small 
changes in experimental conditions. A quality control sample solution containing 20 
ug ml"1 of the drug was analyzed five times using methods A and B. The results 
showed that the mean % recovery ± RSD was found to be 99.98 ± 0.34 and 100.02 ± 
0.35 for methods A and B, respectively. 
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Analytical performance of the proposed methods 
Under the optimized experimental conditions, the absorbance values for 
methods A and B were found to be proportional to the concentration of 
esomeprazole magnesium over the ranges 2 - 48 and 10 - 100 u,g ml"1 with molar 
absorptivity of 2.113 x 104 and 4.565 x 1041 mol"1 cm"1, respectively. The regression 
equation, correlation coefficient, limits of detection and quantitation, confidence 
interval of intercept and slope at 95% confidence level and variance (So2) of 
calibration line were evaluated and summarized in Table 4.1. In both the methods, 
the value of correlation coefficient was 0.9999, which indicated the good linearity of 
calibration lines. The low values of variance of calibration lines (8.47 x 10"6 and 
6.62 x 10"7 for methods A and B, respectively) pointed towards good reproducibility 
of the procedures. It is drawn out from the relation, t = a/Sa [14], that the values of 
the intercept of the regression lines are close to zero. The student's t-test has 
confirmed that the experimental intercepts, a, for methods A and B are not 
significantly different from the theoretical value of zero because the t-values 
calculated from the above relation were found to be 0.152 and 1.074 for methods A 
and B, respectively which did not exceed the tabulated t-values, t = 2.306, v = 8 for 
method A and t = 2.447, v = 6 for method B at 95% confidence level. Therefore, it is 
concluded that the proposed procedures are completely free from constant errors. 
The accuracy and precision of the proposed methods A and B were evaluated 
at three concentration levels: 8, 24, 48 ug ml"1 and 10, 50 and 100 jj,g ml"1, 
respectively. The % relative error and relative standard deviation are summarized in 
Table 4.2. As can be seen from Table 4.2 that the % relative error and relative 
standard deviation were < 0.4 and 0.62 %, respectively. The results of the recovery 
experiments are summarized in Table 4«3. It is evident from the table that % 
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Table 4.1 
Optical and validation data for the determination of esomeprazole magnesium 
Parameters 
Wavelength (nm) 
Beer's law limit (u.g ml"1) 
Molar absorptivity (1 mor'cm" 
Linear regression equation 
±tS, 
±tsb 
Correlation coefficient (r) 
' ) 
Variance (S02) of calibration line 
Detection limit (fig ml'1) 
Quantitation limit (u.g ml"') 
Method A 
365 
2-48 
2.113 x 104 
A = 2.527 x 10"" + 
2.75 x 10"2C 
4.608 x 10"3 
1.584 x 10"4 
0.9999 
8.47 x 10"6 
0.35 
1.06 
Method B 
380 
10-100 
4.565xl04 
A = 6.027 x lO^+SSO* 10"3C 
1.558 x 10"3 
2.609 x 10"5 
0.9999 
6.62 x 10"7 
0.46 
1.38 
±t Sa and ±t Sb are confidence limits for intercept and slope, respectively 
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Table 4.2 
Test of accuracy and precision of the proposed methods 
Proposed methods 
Method A 
Intra day assay 
Inter day assay 
Method B 
Intra day assay 
Inter day assay 
Concentration 
(US ml"1) 
Taken Found ± SDa 
8 
24 
48 
8 
24 
48 
10 
50 
100 
10 
50 
100 
8.01 ±0.04 
24.04 ±0.04 
48.03 ±0.08 
8.02 ± 0.04 
24.01 ±0.05 
48.04 ±0.08 
10.03 ±0.05 
49.98 ±0.08 
100.01 ±0.07 
10.04 ±0.06 
50.01 ±0.11 
100.04 ±0.07 
Error 
(%) 
0.12 
0.16 
0.06 
0.25 
0.04 
0.08 
0.30 
0.04 
0.01 
0.40 
0.02 
0.04 
RSDa 
(%) 
0.494 
0.173 
0.166 
0.550 
0.186 
0.162 
0.512 
0.149 
0.069 
0.621 
0.220 
0.074 
SAEb 
0.018 
0.019 
0.036 
0.019 
0.020 
0.035 
0.064 
0.034 
0.031 
0.028 
0.049 
0.033 
C.L.C 
0.050 
0.052 
0.099 
0.055 
0.056 
0.096 
0.064 
0.093 
0.087 
0.077 
0.137 
0.092 
aMean for five independent determinations. 
bSAE, standard analytical error. 
CC.L., confidence limit at 95% confidence level and four degrees of freedom (t = 2.776). 
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Table 4.3 
Determination of esomeprazole in pharmaceutical formulations by standard addition technique 
Formulations Method A Method B 
Concentration (ug ml'1) Concentration (ug ml"1) 
Taken Added Found ±SD a Recovery RSDa C.L.b Taken Added Found ±SDa Recovery RSDa C.L.b 
Nexpro-20 
(Torrent) 
Raciper-20 
(Ranbaxy) 
Esoz-20 
(Glenmark) 
16 
16 
16 
16 
16 
16 
16 
32 
16 
32 
16 
32 
32.00 ± 0.05 
48.04 ± 0.08 
31.99 ±0.07 
48.02 ± 0.08 
32.01 ±0.05 
48.03 ± 0.08 
(%) 
100.03 
100.08 
99.99 
100.06 
100.01 
100.07 
(%) 
0.162 
0.158 
0.021 
0.166 
0.164 
0.159 
0.065 
0.094 
0.083 
0.098 
0.066 
0.095 
30 
30 
30 
30 
30 
30 
30 
60 
30 
60 
30 
60 
59.99 ±0.06 
90.00 ± 0.07 
59.98 ±0.06 
89.99 ± 0.07 
59.99 ± 0.06 
90.00 ± 0.07 
(%) 
99.99 
100.00 
99.98 
99.99 
99.99 
100.00 
(%) 
0.106 
0.077 
0.093 
0.079 
0.099 
0.078 
0.079 
0.086 
0.069 
0.088 
0.074 
0.087 
aMean for five independent determinations. 
bC.L., confidence limit at 95% confidence level and four degrees of freedom (t = 2.776). 
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recovery and relative standard deviation were in the range of 99.99 - 100.07 % and 
0.02 - 0.17% for method A and 99.98 - 100.01 % and 0.08 - 0.11% for method B, 
respectively. These results indicated that there is no interference from the common 
excipients presents in tablet formulations. The proposed methods and reference 
method were applied to the determination of esomeprazole magnesium in tablet 
formulations. The results obtained by the proposed methods were compared 
statistically with those obtained by the reference method (Table 4.4). The assay 
results showed that student's t- and F- values did not exceed the theoretical ones at 
95% confidence level. In all cases, the values of lower and upper limits based on 
recovery experiments were found to be within ± 2%. 
CONCLUSION 
The drug is a complex of magnesium, which selectively reacts with 5-
sulphosalicylic acid in methanol to form coloured complex peaking at 365 nm 
(method A). The drug is showing no sign of reaction with reagents devoid of 
sulfonic group such as salicylic acid, benzoic acid and phenol. Method B is selective 
as the drug is containing carbon as a prochiral center (a-carbon) adjacent to 
sulphoxide preferentially reacts with N-bromosuccinimide in acetone, hence 
undergoes a-bromination of drug, which absorbed maximally at 380 nm. The drug 
gives positive response only to those oxidizing agents, which contain Br in their 
moiety. Hence, the two methods are selective, but method A is more superior due to 
the formation of ternary complex and rapid analysis (5 min) with low detection limit 
(0.35 u.g ml'1) compared to method B, requiring more analysis time (12 min) with 
high limit of detection (0.46 u.g ml"1). Therefore methods A and B can be used for 
the routine quality control analysis of esomeprazole magnesium in industries, 
research laboratories and hospitals. 
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Table 4.4 
Analysis of esomeprazole magnesium of the proposed methods using point and interval 
hypothesis tests at 95% confidence level 
Formulations Method A Method B Reference method 
Recovery RSD Recovery RSD Recovery RSD 
(%) (%) (%) (%) (%) (%) 
100.02 0.35 
99.98 0.33 
Nexpro-20 
(Torrent) 
Raciper-20 
(Ranbaxy) 
Esoz-20 
(Glenmark) 
99.98 
0L=O.988 
t =0.09 
100.06 
9L=0.989 
t=0.18 
99.99 
0L=O.987 
t =0.04 
0.33 
9u=1.011 
F=1.01 
0.33 
9u=1.012 
F= 1.02 
0.35 
9u=1.012 
F=1.17 
99.98 
6L=0.987 
t =0.30 
100.01 
9L=0.992 
t=0.59 
100.01 
9L=0.988 
t =0.05 
0.34 
9u=1.012 
F= 1.08 
0.35 
9u=1.009 
F= 1.05 
0.32 
9u=1.012 
F= 1.09 
100.01 0.36 
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CHAPTER-5 
OPTIMIZATION AND VALIDATION OF 
SPECTROPHOTOMETRIC METHODS FOR 
THE QUANTITATION OF RABEPRAZOLE 
SODIUM I N COMMERCIAL DOSAGE 
FORMS 
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INTRODUCTION 
Rabeprazole sodium is chemically known as 2-({[4-(3-methoxy propoxy)-3-
methyl-2-pyridyl] methyl} sulfmyl)-lH-benzimidazole sodium (Ci8H2oN3Na03S = 
381.4). Rabeprazole sodium represents the newest class of antisecretory agents that 
are well known for their proton pump (H+ / K+-ATPase) inhibitor activity, most 
profoundly diminishing gastric acid secretion and thus, lowering the luminal 
concentration of hydrogen ions. It has recently been demonstrated that rabeprazole 
sodium is the only proton pump inhibitor among tested (omeprazole, lansoprazole) 
that augments gastric mucin content [1]. It has proven efficacy in healing, symptom 
relief and prevention of relapse peptic ulcers and gastro-oesophageal reflux disease. 
It is an important alternative to H2 antagonists and an additional treatment option to 
other proton pump inhibitors in the management of acid related disorders. 
The drug is officially listed in Martindale The Extra Pharmacopoeia [2]. The 
assay of drug in bulk and formulations is not cited in the United States 
Pharmacopoeia or British Pharmacopoeia. In view of the great importance and wide 
use of rabeprazole sodium, different analytical methods have been reported for its 
determination which include high performance liquid chromatography [3-5], liquid 
chromatography coupled with tandem mass spectrometry [6], capillary 
electrophoresis [7], and UV-spectrophotometry [8]. These reported methods are 
sensitive but expensive and require laboratories clean up procedure prior to analysis 
of drug. Moreover, UV spectrophotometry requires the elimination of matrix effects, 
since many compounds present in tablet formulations also absorb in UV region. 
These elimination efforts make the method more complicated and laborious. 
Spectrophotometry in visible region is attractive because of speed, and simplicity. 
Extractive spectrophotometric methods have been utilized for the quantitation of 
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rabeprazole sodium in pharmaceutical formulations based on chloroform extractable 
ion pair complexes of the drug with bromothymol blue, bromocresol green, 
bromocresol purple, amido black and alzarin Red S in acidic medium at 424, 430, 
422, 636 and 437 ran, respectively [9]. 
This chapter describes two visible spectrophotometric methods for the 
determination of rabeprazole sodium in commercial dosage forms. Method A is 
based on the reaction of rabeprazole sodium with 3-methyl-2-benzothiazolinone 
hydrazone hydrochloride (MBTH) in the presence of ammonium cerium (IV) nitrate 
in acetic acid medium to form coloured species which absorbs maximally at 470 ran. 
Method B utilizes the reaction of rabeprazole sodium with l-chloro-2,4-
dinitrobenzene (CDNB) in dimethyl sulphoxide (DMSO) to form Meisenheimer 
complex peaking at 420 ran. The reaction conditions are optimized and validated as 
per ICH guidelines [10]. 
EXPERIMENTAL 
Apparatus 
Shimadzu (UV-1240, Shimadzu Corporation, Kyoto, Japan) and Milton Roy 
Company (20D+, USA) spectrophotometers were used for absorbance 
measurements. 
Reagents and Materials 
All chemicals used were of analytical reagent grade. 
• MBTH (s.d. fine-chem Ltd., Mumbai, India) solution (1.7 x 10"3 M) was freshly 
prepared in distilled water. 
• Ammonium cerium (IV) nitrate (Fluka Chemie AG) solution (2.0 x 10"2 M) was 
prepared in 3.5 x 10"2 M acetic acid (Merck, India). 
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• CDNB (Fluka Chemie AG) solution (5.59 x 10"2 M) was prepared in DMSO 
(Merck, India). 
Rabeprazole sodium reference standard was supplied by Hetero Drug Ltd., 
Hyderabad, India (Batch No.: RSO250305). Tablet formulations of rabeprazole 
sodium such as Rabicip-20 (Cipla, Mumbai, India), Rablet-20 (Lupin, Mumbai, 
India), Rapeed-20 (Alkem, Mumbai, India) were purchased from local drug stores. 
Test solutions 
• Rabeprazole sodium (1 mg ml"1) solution was prepared in distilled water. 
• Rabeprazole sodium (0.75 mg ml'1) solution was prepared in DMSO. 
Proposed Procedures for the quantitation of rabeprazole sodium 
Method A 
Aliquots (0.14 - 1.4 ml) of standard rabeprazole sodium (1 mg ml"1) solution 
corresponding to 14 - 140 jj,g ml'1 were pipetted into a series of 10 ml volumetric 
flasks. To each flask, 1.7 ml of 2.0 * 10"2 M ammonium cerium (IV) nitrate and 2.0 
ml of 1.71 x 10'3MMBTH were added and diluted to volume with distilled water. 
The contents of the flask were mixed well and kept for 10 min at room temperature 
(25 ± 1°C) to complete the reaction. The absorbance of each solution was measured 
at 470 nm against the reagent blank prepared simultaneously except drug within the 
stability time period of 6 h. The amount of the drug was calculated either from the 
calibration graph or the corresponding regression equation. 
Method B 
Into a series of boiling test tubes, different volumes (0.05 - 1.1 ml) of standard 
rabeprazole sodium (0.75 mg ml"1) solution corresponding to 7.5 - 165 u.g ml"1 were 
pipetted. To each test tube, 2.5 ml of 5.92 x 10"3 M CDNB was added, mixed well 
and heated on water bath for 10 min at 45 ± 1°C. After cooling at room temperature, 
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the contents of the test tube were transferred to a 5 ml volumetric flask and the 
volume was completed with DMSO. The absorbance was measured at 420 nm 
against the reagent blank treated similarly within the stability period of 24 h. 
Procedure for the quantitation of rabeprazole sodium in tablet formulations 
Five commercially available tablets of 20 mg strength of rabeprazole sodium 
were taken in distilled water and DMSO separately and kept for 10 min for complete 
dispersion of the drug. The distilled water and DMSO extracts were filtered through 
Whatmann No. 42 filter paper (Whatmann International Limited, Kent, UK) in 100 
ml volumetric flasks individually. The left residues were washed well with 5><10 
ml portions of distilled water or DMSO, as the case may be, for complete recovery 
of the drug and diluted to volume with the corresponding solvent. The amount of 
drug in commercial tablets was assayed following the proposed procedures. 
Procedure for reference method 
Aliquots (0.1 - 2.0 ml) of standard rabeprazole sodium (0.5 mg ml'1) 
corresponding to 10 - 100 ug ml"1 were pipetted into a series of 10 ml volumetric 
flasks and diluting to volume with distilled water. The absorbance was recorded 
against the solvent blank at 290 nm. The amount of the drug in a given sample can 
be estimated either from the calibration graph or the corresponding regression 
equation. 
Method validation 
Solution stability 
The stability of reference rabeprazole sodium and quality control sample 
solutions at room temperature was evaluated with the help of UV-visible spectra and 
thin layer chromatography using TLC plates coated with silica gel G (Merck, 
Mumbai, India) and acetone-toluene-methanol (v/v/v/: 9:9:1.5) as mobile phase. 
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Specificity and selectivity 
The specificity and selectivity of the proposed methods was ascertained by 
analyzing rabeprazole sodium in presence of excipients such as mannitol, 
magnesium oxide, low substituted hydroxylpropyl cellulose, magnesium stearate, 
hypromellose pthalate diacetylated monoglycerides, talc, titanium dioxide, yellow 
iron oxide and carnauba wax. 
Ruggedness and robustness 
For the evaluation of ruggedness of methods A and B, the contents of 
rabeprazole sodium (80 ug ml"1) was analyzed following the proposed procedures (A 
and B) using Spectronic 20D+ and Shimadzu UV 1240 spectrophotometers. The two 
results were compared in terms of % recovery ± RSD. 
In the similar manner, proposed methods robustness was evaluated by 
analyzing rabeprazole sodium (80 (ig ml"1) under the influence of small variations of 
experimental variables. The exactness of each operational parameter was checked by 
varying one experimental parameter at a time keeping the other parameters constant 
and the % recovery ± RSD of drug was calculated. 
Linearity 
For evaluation of linearity, the contents of rabeprazole sodium was determined 
at nine concentration levels: 14, 15, 20, 30, 40, 60, 100, 120 and 140 ug ml"1 for 
method A and 7.5, 10.5, 12,15, 75, 90, 125,150 and 165 ug ml"1 for method B. Each 
concentration was independently analyzed for five times. 
Limits of detection and quantitation 
The limits of detection and quantitation were evaluated from the following 
equations: 
LOD = 3.3x^-
b 
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Accuracy and precision 
Three concentrations levels of reference rabeprazole sodium solution within 
the linearity range of methods A and B were selected: 14, 60 and 140 ug ml'1 for 
method A and 10.5, 65 and 165 ug ml'1 for method B. Five independent analyses at 
each concentration level was performed within one day (intra day precision). This 
analysis was repeated for five consecutive days too (inter day precision). 
Equivalence testing 
For pharmaceutical analysis, a bias of ± 2.0 % is acceptable [11] and can be 
calculated statistically [12] using the following quadratic equation: 
e
2
^-Slt,ab2lnx)+e{-2^~2) + ^2-S2ptJln2)=Q 
where x, and x2 are mean values based on ni and m measurements, respectively. Sp 
is the pooled standard deviation and itab is the tabulated one-sided t-value, with ni + 
n2 -2 degrees of freedom at 95% confidence level. 
RESULTS AND DISCUSSION 
Method A 
The literature citation revealed that MBTH on oxidation with cerium (IV) in 
acidic medium produces an active electrophilic intermediate [13] which further 
reacts with iminoheteroaromatic compounds such as indole, carbazole, 
phenothiazine and benzimidazole resulting in the formation of a coloured azo 
cationic species [14,15]. Benzimidazole is the iminoheteroaromatic compound, 
which undergoes electrophilic substitution in the benzene ring. The order of 
substitution is 7 > 6 > 5 > 4 [16]. Rabeprazole sodium is a water soluble proton 
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pump inhibitor having benzimidazole as the active group and hence undergoes 
similar electrophilic substitution at position 7 of the benzene ring with the 
electrophilic intermediate of MBTH in acetic acid medium resulting in the formation 
of azo cation species, which absorbs maximally at 470 nm. The blank consisting of 
MBTH and Ce(IV) in acidic medium absorbed at 350 nm. The absorption spectra 
are shown in Fig. 5.1. The combining ratio was evaluated by Bent and French 
method [17]. The plot of log absorbance vs log [rabeprazole sodium] or [MBTH] or 
[Ce(IV)] gave values of the slopes of 1, 1 and 0.98, respectively (Fig. 5.2). Hence it 
is concluded that the reaction proceeds in the molar ratio of 1:1:1. The reaction 
sequence is shown in Scheme 5.1. 
Method B 
Polynitroaromatic and halopolynitroaromatic compounds interact with a 
variety of Bronsted bases to give brightly coloured species due to the activating 
effect of a nitro group with nucleophilic displacement of an ortho substituent, 
especially halogen. Therefore, in general addition-elimination mechanism via an 
intermediate o, or Meisenheimer complex is accepted [18]. Halogen may be 
displaced by nitrogen bases (nucleophiles) such as imidazole, benzimidazole, 1,3,5-
trimethyl pyrazole and 3,5-dimethyl pyrazole [19]; and piperidine [20]. It was 
reported that piperidine is a nitrogen Jbase interacted with 1,3,5-trinitrobenzene in 
DMSO to form coloured species of 1,3,5 - trinitrophenyl piperidine. In this reaction, 
2 moles of nitrogen base were utilized with one mole of 1,3,5-trinitrobenzene. 
Rabeprazole sodium is a nitrogen base due to the presence of benzimidazole group 
which reacts with CDNB in DMSO at 45 ± 1°C resulting in the formation of 
154 
1.8 
1.6 -
1.4 
1.2 -
0 
g 1.0 
CO 
xi 
o 
w 
xi 0.8 
< 
0.6 
0.4 
0.2 
0.0 ' * T 1 1 I • »••¥ 1 1 r 
200 250 300 350 400 450 500 550 600 650 700 
Wavelength (nm) 
Fig. 5.1. Absorption spectra of (a) rabeprazole sodium (40.0 \xg ml"1) in distilled 
water (b) blank solution: 3.4 xlO'3 M ammonium cerium (IV) nitrate and 2.57 
xlO"4 M MBTH in 5.95 xlO"3 M acetic acid (c) sample solution: blank solution + 
100.0 |j.g ml" rabeprazole sodium. 
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Meisenheimer complex which absorbs maximally at 420 nm. The blank consisting 
of CDNB in DMSO has a characteristic band at 353 nm (Fig. 5.3). 
The stoichiometry was established by mole ratio method. The results are 
shown in Fig 5.4. It is apparent from the figure that the combining molar ratio 
between rabeprazole sodium and 1-chloro 2,4-dinitro benzene is 2:1. This 
stoichiometric ratio is comparable with the previous results showed by 1,3,5-
trinitrophenyl piperidine complex. The reaction sequence is shown in Scheme 5.2. 
Solution stability 
The stability of rabeprazole sodium solution was ascertained in distilled water, 
DMSO and acetic acid. The reference drug and quality control sample solutions 
prepared in DMSO showed no change in the absorption spectra for 6 h at room 
temperature in DMSO, distilled water and 3.50 * 10"4 - 7.0 x 10'3 M acetic acid. A 
single spot was observed in reference drug and quality control sample solutions with 
Rf value of 0.68, which corresponds to the rabeprazole sodium. The reaction 
products of methods A and B were also examined by TLC, which indicated the Rf 
values of 0.45 and 0.58, respectively. 
Optimization of variables 
The optimization of variables for methods A and B was assessed by testing 
several parameters such as temperature, heating time, solvents, concentrations of 
ammonium cerium (IV) nitrate, MBTH and CDNB. 
Method A 
Effect of reaction time 
The influence of the reaction time on the absorbance of the product was 
studied by taking 100 ug ml"1 of rabeprazole sodium with 1.7 ml of 2 xlO'2 M 
ammonium cerium (IV) nitrate and 1.5 ml of 1.7x10"3 M MBTH in 10 ml volumetric 
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Fig. 5.3. Absorption spectra of (a) 75.0 u.g ml"1 rabeprazole sodium in DMSO 
(b) blank solution: 1.18 xiO"2 M CDNB in DMSO (c) sample solution: 2.37 xlO"2 
M CDNB + 150 ng ml"1 rabeprazole sodium in DMSO. 
159 
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 
Mole ratio [CDNB] / [Rabeprazole sodium] 
Fig. 5.4. Mole ratio plot for stoichiometric ratio between rabeprazole 
sodium and CDNB for method B. 
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flask. It was found that the maximum absorbance was achieved at 8 min of reaction 
and remains constant up to 12 min (Fig. 5.5). Therefore, a time of 10 min at room 
temperature was selected as an optimum reaction time. 
Effect of the concentration of ammonium cerium (IV) nitrate 
The influence of the concentration of ammonium cerium (IV) nitrate on the 
absorbance of the product was investigated in the range of 2.0 xlO"4 - 4.0 *10"3 M. It 
was observed that the maximum absorbance was attained with 3.0 x 10"3 M 
ammonium cerium (IV) nitrate (Fig. 5.6) and remained constant up to 4.0 x 10"3 M. 
Therefore, 3.4 x 10"3 M ammonium cerium (IV) nitrate was taken as the optimum 
concentration for the determination process. 
Effect of the concentration of MBTH 
The effect of the concentration of MBTH on the absorbance of the product 
was studied in the range of 1.71 x 10'5 - 3.25 x 10' M. A constant absorbance was 
obtained with 1.88 x 10"4 M MBTH, beyond this further increase in the 
concentration of MBTH up to 3.25 x 10"4 M, resulted in no change in the absorbance 
(Fig 5.7). Thus, 3.25 x 10"4 M MBTH was adopted as an optimum concentration for 
the maximum absorbance in the determination procedure. 
Method B 
Effect of temperature and time 
The effect of temperature on the reaction between rabeprazole sodium (150 jag 
ml"1) and CDNB (2.84 xlO"2 M) was studied at 35, 40, 45 and 50°C. It was observed 
that the equilibrium was attained at 18, 14, 8 and 8 min at temperature of 35, 40, 45 
and 50°C, respectively. To speedup the determination process and for the sake of 
good recovery results, optimum temperature of 45°C was chosen for the estimation 
of rabeprazole sodium. It was also observed that the absorbance at 45 °C was 
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Fig. 5.5. Effect of time on the absorbance of colour reaction for 
Method A 
163 
0.0000 0.0006 0.0012 0.0018 0.0024 0.0030 0.0036 
[Ammonium cerium (IV) nitrate] (M) 
0.0042 
Fig. 5.6. Effect of the concentration of ammonium cerium (IV) nitrate 
on the absorbance of coloured complex (Method A). 
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Fig. 5.7. Effect of the concentration of MBTH on the absorbance of coloured 
complex (Method A). 
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constant in the range of 8-12 min (Fig 5.8). Therefore, the optimum time of heating 
for the maximum absorbance was chosen to be 10 min for determination procedure. 
Effect of the concentration ofCDNB 
The influence of CDNB concentration on the absorbance of yellow coloured 
complex was studied in the range of 1.18* 10"3-3.32xl0'2M. It was found that the 
maximum absorbance was obtained in the range of 2.37 x 10" - 3.32 xlO" M 
CDNB (Fig 5.9). Therefore, the optimum concentration of 2.84 x 10"2 M CDNB was 
recommended for determination procedure. 
Statistical performance of the analytical data 
The calibration curves were constructed by plotting absorbance against 
concentration of rabeprazole sodium for the proposed methods. Beer's law was 
obeyed over the concentration ranges 14-140 jag ml"1 and 7.5-165 ug ml"1 with molar 
absorptivity of 4.104xl031 mor'cm"1 and 2.069 x 1031 mol"1cm"1for methods A and 
B, respectively. The calibration data were fitted to the equation, A = a + bC, where 
A is the absorbance at relevant XmaX; C is the concentration in u,g ml"1; b is the slope 
and a is the intercept of calibration. The regression parameters are summarized in 
Table 5.1. The high values of correlation coefficients (0.9999) for both methods 
indicated excellent linearity. In order to verify that the proposed methods are free 
from procedural error, the experimental intercept of the calibration lines were tested 
for significance of the deviation from the theoretical intercept as zero. For this 
justification, the values oft-calculated from the relation, t = a / Sa [18] were found to 
be 0.246 and 1.596 for methods A and B, respectively, which did not exceed the 
theoretical t-value (2.365) at 95% confidence level. This indicated that the intercepts 
for methods A and B are not significantly different from zero. 
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Fig. 5.8. Effect of time on the absorbance of colour reaction for Method B. 
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Fig. 5.9. Effect of the concentration of CDNB on the absorbance of yellow 
coloured complex (Method B). 
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Table 5.1 
Summary of validation data for the determination of rabeprazole sodium 
Parameters Method A Method B 
Wavelength (nra) 
Beer's law limit (u.g ml"1) 
Molar absorptivity (1 mor'cm"') 
Linear regression equation 
±tSab) 
±tSbb) 
Correlation coefficient (r) 
Variance (S02) of calibration line 
Detection limit (p.g ml"1) 
Quantitation limit (|0.g ml"1) 
475 
14-140 
4.104 x 103 
A = 6.041 x 10"4 + 
1.07xl0'2C 
6.828 x 10"3 
9.065 x 10"5 
0.9999 
1.989 x 10"5 
1.38 
4.18 
420 
7.5-165 
2.069 x 103 
A= 1.020 x 10"3 + 
5.0 x 10"3C 
1.774 x 10"3 
1.886 x 10"5 
0.9999 
1.513 x 10"6 
0.75 
2.27 
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Ruggedness and robustness 
The ruggedness of methods A and B was evaluated by assaying the contents of 
rabeprazole sodium in tablet formulation using Spectronic 20D+ and Shimadzu UV 
1240 spectrophotometers. The percent recoveries ± RSD resulted from Spectronic 
20D+ spectrophotometer (100.02 ± 0.06 and 100.05 ± 0.09 for methods A and B, 
respectively) and Shimadzu UV 1240 (100.05 ± 0.06 and 100.04 ± 0.06 for methods 
A and B, respectively) were compared. The results agreed well within the acceptable 
limits with permissible bias. 
The robustness of the methods A and B relative to each operational parameter 
was challenged. The operational parameters investigated were as follows: 
Method A 
• room temperature, 25 ± 1°C 
• reaction time, 10 ± 2 min 
• volume of lJxlO"3 M MBTH, 1.5 ± 0.4 ml 
• volume of 2.0 x 10" M ammonium cerium (IV) nitrate, 1.7 ± 0.3 ml 
Method B 
• heating temperature, 45 ± 1°C 
• reaction time, 10 ± 2 min 
• volume of 5.59 xlO"3 M CDNB, 2.4 ± 0.4 ml 
The robustness of the proposed methods was assessed by analyzing active 
drug content in Rabicip-20. The quality control sample solution containing 80 jig 
ml"1 of the drug was analyzed five times using methods A and B. The percent 
recoveries ± RSD for methods A (100.02 ± 0.09) and B (100.05 ± 0.08) were found 
to be appreciable, thus indicated that the proposed methods are robust. 
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Specificity and selectivity 
The proposed spectrophotometric conditions were found to be specific and 
selective in the presence of tablet excipients. It was observed that common 
excipients present in tablet formulations did not cause any significant interference. 
Accuracy and precision 
The intra day precision was evaluated by determining rabeprazole sodium at 
three concentration levels for five times within the same day (Table 5.2). As can be 
seen from Table 5.2 that the percent relative error and relative standard deviation 
(%) were in the ranges of 0.014 - 0.571; 0.040 - 0.47 and 0.018 - 0.190; 0.040 - 0.45 
for methods A and B, respectively. Also, the inter day precision was evaluated over 
a period of five days and the percent relative error and relative standard deviation 
(%) were found to be 0.007 - 0.429; 0.07 - 0.56 and 0.024 - 0.286; 0.040 - 0.45 for 
methods A and B, respectively. 
The accuracy of the proposed methods A and B was ascertained by recovery 
studies using standard addition method. The results are summarized in Table 5.3. 
The mean recoveries and RSD for methods A and B were in the ranges 100.04 ± 
0.065 - 100.16 ± 0.194 % and 100.01 ± 0.042 - 100.05 ±0.109 %, respectively 
which can be considered to be very satisfactory. 
The proposed procedures have been successfully applied to quantitate 
rabeprazole sodium in commercial dosage forms. The results obtained by methods A 
and B were compared with those of reference method in terms of mean recovery, 
RSD, 0L, 0u, t- and F- values (Table 5.4). It is evident from Table 5.4 that the assay 
results showed good agreement between proposed methods and the reference 
method as t- and F- values were less than the theoretical ones at 95 % confidence 
level and 0L and 0u were less than ± 2.0 %. Therefore, it is concluded that the 
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Table 5.2 
Summary of accuracy and precision results of the proposed methods 
Proposed methods 
Method A 
Intra day assay 
Inter day assay 
Method B 
Intra day assay 
Inter day assay 
Concentration 
(W? ml"1) 
Taken Found ± SD 
14.0 
60.0 
140.0 
14.0 
60.0 
140.0 
10.5 
75.0 
165.0 
10.5 
75.0 
165.0 
14.08 ±0.07 
60.08 ±0.08 
139.98 ±0.05 
14.06 ±0.08 
60.00 ±0.08 
140.01 ±0.09 
10.52 ±0.05 
75.05 ±0.08 
165.03 ±0.07 
10.53 ±0.05 
75.04 ±0.08 
165.04 ±0.07 
RSDa 
(%) 
0.47 
0.13 
0.04 
0.56 
0.14 
0.07 
0.45 
0.11 
0.04 
0.45 
0.11 
0.04 
R.E.b 
(%) 
0.571 
0.133 
0.014 
0.429 
0.016 
0.007 
0.190 
0.066 
0.018 
0.286 
0.053 
0.024 
SAEb 
0.029 
0.035 
0.023 
0.035 
0.036 
0.042 
0.021 
0.035 
0.029 
0.022 
0.037 
0.031 
C.L.C 
0.082 
0.073 
0.097 
0.097 
0.101 
0.116 
0.059 
0.098 
0.080 
0.058 
0.103 
0.087 
1
 Mean for five independent analyses. 
' R.E. and SAE indicate relative error (%) and standard analytical error. 
C.L. is the confidence limit at 95% confidence level and four degrees of freedom (t = 2.776). 
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Table 5.3 
Summary of results evaluated by standard addition technique for the 
quantitation of rabeprazole sodium in pharmaceutical formulations 
Formulations Amount (ug ml"1) Found ± SDa Recovery ± SAE C.L. 
RSDa 
Taken Added 
Method A 
Rabicip-20 (Cipla) 40 40 80.13 ±0.13 100.16 ±0.156 0.056 0.155 
40 80 120.07 ±0.09 100.06 ±0.077 0.042 0.116 
Rablet-20 (Lupin) 40 40 80.11 ±0.16 100.13 ±0.194 0.069 0.193 
40 80 120.05 ±0.12 100.04 ±0.102 0.054 0.152 
Rapeed-20 40 40 80.03 ±0.16 100.09 ±0.194 0.070 0.193 
(Alkem) 
40 80 120.05 ±0.08 100.04 ±0.065 0.035 0.097 
Method B 
Rabicip-20 (Cipla) 45 45 90.05 ± 0.09 100.04 ±0.096 0.039 0.108 
45 90 135.04 ±0.07 100.03 ± 0.048 0.029 0.081 
Rablet-20 (Lupin) 45 45 90.04 ±0.09 100.05 ± 0.099 0.089 0.247 
45 90 135.05 ±0.06 100.03 ±0.042 0.025 0.072 
Rapeed-20 45 45 90.02 ±0.10 100.03 ±0.109 0.044 0.123 
(Alkem) 
45 90 135.01 ±0.06 100.01 ±0.045 0.027 0.075 
Mean for five independent analyses 
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Table 5.4 
Summary of comparison results of the proposed methods with the reference method at 95% confidence level 
Formulations Method A Method B Reference method 
Recovery RSDa t-& F b eL&9uC Recovery RSDa t - & F 6 9L & Qu° Recovery RSDa 
(%) (%) (%) (%) (%} (%) 
Rabicip-20 100.04 0.064 t = 0.052 6L = 0.987 100.04 0.065 t = 0.053 9L = 0.990 100.06 0.068 
(Cipla) F = 1.162 9u= 1.012 F = 1.153 9u= 1.010 
Rablet-20 100.02 0.094 t =0.246 9L = 0.992 100.05 0.088 t =0.133 9L = 0.989 99.99 0.087 
(Lupin) F = 1.132 9 y = 1.009 F = 1.008 Qu= 1.012 
Rapeed-20 100.05 0.064 t = 0.098 0L = 0.988 100.04 0.064 t =0.052 9L = 0.987 100.06 0.069 
(Alkem) F = 1.158 Gy = 1.013 F = 1.163 9u= 1.012 
Mean for five independent analyses 
Theoretical t-value (v =8) and F-value (v =4,4) at 95% confidence level are 2.306 and 6.39, respectively. 
C9L = 0.98 and 0y = 1.02 are acceptable bias, based on recovery experiments and are within ±2%. 
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proposed methods A and B are applicable for routine quality control analysis of 
rabeprazole sodium in commercial dosage forms with acceptable recovery results 
less than ±2.0 %. 
CONCLUSION 
The proposed methods provide simple, accurate and reproducible quantitative 
analysis for the assay of rabeprazole sodium in commercial dosage forms. Both 
methods are specific and selective. In addition, the proposed methods have high 
molar absorptivity (4.1 x 1031 moP1 cm-1 for method A and 2.07 x 1031 mol""1 cm-1 
for method B) with broad linear dynamic range (14 - 140 ug ml"1 for method A and 
7.5 - 165 jag ml"1 for method B) and high tolerance limit for excipients found in 
dosage forms. Therefore the proposed methods are recommended for the routine 
quality control analysis of rabeprazole sodium in commercial dosage forms. 
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Kinetic Spectrophotometric Analysis of Pantoprazole in 
Commercial Dosage Forms 
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A kinetic spectrophotometric method has been developed which is based on the oxidation of pantoprazole with Fe(IIl) in 
sulfuric acid medium. Fe(III) subsequently reduces to Fe(ll), which is coupled with potassium ferricyanide to form 
Prussian blue. The reaction is followed spectrophotometrically by measuring the increase in absorbance with time (1-8 
min) at 725 nm. The initial rate method is adopted for constructing the calibration graph, which is linear in the 
concentration range of 5 - 90 )ig ml ' . The regression analysis yields the calibration equation, v = 3.467 x 10"6 + 4.356 x 
10 5C. The limits of detection and quantitation are 1.46 and 4.43 )ig ml"1, respectively. The proposed method was 
optimized and validated both statistically and through recovery studies. The experimental true bias of all samples is 
< ±2.0%. The method has been successfully applied to the determination of pantoprazole in pharmaceutical preparations. 
(Received November 24, 2005; Accepted February 22,2006) 
Introduction 
Pantoprazole, 5-difluoromethoxybenzimidazole-2-yl 3,4-
dimethoxy-2-pyridylmethyl sulfoxide (CAS, 102625-70-7; 
MW, 383.4) is an irreversible proton pump (HVK+-ATPase) 
inhibitor (PPI) that decreases acid secretion from gastric parietal 
cells; its major metabolite is pantoprazole sulfone.1 The 
structural formulae are shown in Scheme 1. It is also effective 
in Zollinger-Ellison syndrome and in preventing ulcer rebleeding. 
Thus pantoprazole is a valuable alternate to other PPIs in the 
treatment of acid-related disorders. The drug is officially listed 
in Martindale The Extra Pharmacopoeia.2 The assay of drug in 
bulk and dosage forms is not announced in any pharmacopoeia 
and therefore requires much more investigation in order to 
assure the exact quantity of drug in pharmaceutical formulations. 
A literature survey reveals that high performance liquid 
chromatography,3"5 capillary zone electrophoresis,6 and 
voltammetry7 have been employed for its quantification. The 
above-mentioned techniques, of course, are sensitive enough 
but are expensive. Spectrophotometry is the technique of 
choice even today due to its inherent simplicity. It is frequently 
used in the laboratories of the developing countries to overcome 
a variety of analytical problems. In the literature only a few 
spectrophotometric methods have been reported. Two derivative 
spectrophometric procedures8'9 have been described for the 
determination of pantoprazole in drug formulations. The drug 
content in pharmaceutical preparations has been determined 
spectrophotometrically10 in the visible region based on the 
reaction of drug with Fe(III) to form an orange-colored chelate, 
which absorbed maximally at 455 nm. The drug forms a ternary 
complex with eosin and copper, which is a basis for its analysis 
at 549 nm." The charge transfer eomplexation reaction between 
the drug and 2,3-dichloro-5,6-dicyano-l,4-ben7.oquinone or 
iodine has been used to quantify the drug spectrophotometrically.11 
f
 To whom correspondence should be addressed. 
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A kinetic spectrophotometric method based on the reaction of 
pantoprazole with l-fluoro-2,4-dinitrobenzene in dimethyl 
sulfoxide medium12 has been reported; this showed a linear 
response over the concentration range of 10.0 - 20.0 (ig ml"'. 
In this paper, a kinetic spectrophotometric method for the 
determination of pantoprazole in drug formulations is described. 
The method is based on the oxidation of pantoprazole with 
Fe(III) in sulfuric acid medium; Fe(III) subsequently reduced to 
Fe(II), which reacts with potassium ferricyanide to form a 
Prussian blue product, absorbing maximally at 725 nm. The 
initial-rate method is applied for the determination of 
pantoprazole. The method is optimized and validated as per the 
guidelines of the International Conference on Harmonisation." 
Experimental 
Apparatus 
A Shimadzu UV-visible spectrophotometer (UVmini-1240, 
Shimadzu Corporation, Kyoto, Japan) was used for all 
absorbance measurements with matched quartz cells. 
OCHj 
r / L / O C H 3 
Pantoprazole 
OCH3 
1 ^ 0 C H 3 
Pantoptiuotc sulfone 
Scheme I 
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Materials and reagents 
All chemicals and reagents were of analytical or 
pharmaceutical grade. Pantoprazole was kindly supplied by 
Concept Pharma Ltd. (Mumbai, India) and was used as the 
reference standard. A standard solution of pantoprazole (0.1 %) 
was prepared by dissolving 50 mg in 50 ml distilled water. 
Pharmaceutical formulations of pantoprazole such as Pantec 20 
(Concept, Mumbai, India) and Pantodac 20 (Zydus Cadila, 
Ahmedabad, India) were purchased from local markets. 
Ammonium ferric sulfate (3.0 x 10-3 M; Fluka Chemie AG, 
Switzerland) solution was prepared by dissolving 144.66 mg of 
ammonium ferric sulfate in 0.003 M sulfuric acid. Potassium 
ferricyanide (2.5 x 10~3 M; Fluka Chemie AG, Switzerland) 
solution was prepared in distilled water. 
Recommended procedure 
Aliquots of 0.05-0.9 ml standard solutions of pantoprazole 
were pipetted into a series of 10.0 ml standard volumetric 
flasks. To each flask, 1.7 ml of 3.0 x I0~3 M ammonium ferric 
sulfate was added, followed by 1.5 ml of 2.5 x ID"5 M 
potassium ferricyanide. Then the mixture was diluted to 
volume with distilled water at 35 ± l°C. The contents of each 
flask were mixed well and then immediately transferred to the 
spectrophotometric cell. The increase in absorbance was 
recorded at 725 nm as a function of time for 8.0 min. The initial 
rate of the reaction (v) at different concentrations was obtained 
from the slope of the initial tangent to the absorbance-time 
curve. The calibration graph was constructed by plotting the 
initial rate of reaction, v versus concentration of pantoprazole 
(C, Jig ml'1). The amount of the drug was evaluated either from 
the calibration graph or from the regression equation. 
Procedure for the determination of pantoprazole in 
pharmaceutical formulations 
The quality control sample solution containing pantoprazole at 
a concentration of 1.0 mg ml"1 was prepared. The contents of 5 
tablets of 20 mg strength were obtained by gentle peeling of the 
hard coated shells. The contents of the tablets were put in 
distilled water and left for 10.0 min for complete dispersion of 
the drug. Then the solution was filtered through a piece of 
Whatmann No. 42 filter paper (Whatmann International 
Limited, Kent, UK) in a 100 ml standard volumetric flask. The 
residue was washed well with distilled water for complete 
recovery of the drug and then the mixture was diluted up to the 
mark with distilled water. The assay was completed following 
the proposed procedure for the determination of pantoprazole. 
Procedure for the determination of pantoprazole in synthetic 
mixtures 
Synthetic mixtures of pantoprazole were prepared by taking 
various excipients commonly used in tablet dosage forms with 
800 p.g of pantoprazole in 10 ml standard volumetric flask and 
tested to study the interferences of excipients such as sodium 
stearyl fumarate, magnesium stearate, corn starch, lactose and 
talc. 
Procedure for reference method" 
Aliquots of 0.1 - 0.6 ml of 0.1 % pantoprazole were pipetted 
into a series of 10 ml standard volumetric flasks. To each flask, 
6.0 ml of 0.4% 2,3-dichloro-5,6-dicyano-1,4-benzoquinone was 
added and the mixture was diluted to volume with acetonitrile. 
The absorbance was measured against the reagent blank at 457 
nm. The amount of the drug in a given sample was computed 
from the calibration graph. 
Validation 
The proposed kinetic method has been validated for 
specificity, linearity, limit of detection, precision, accuracy and 
recovery. 
Specificity. The reference standard and quality control samples 
of pantoprazole were subjected to stress conditions of light, 
heat, acid, base and oxidants. Each stressed sample was 
measured to determine the content of pantoprazole and the 
results were compared to those for an unstressed time zero 
reference solution. The reference assay value for each 
unstressed product was evaluated and the contents of 
degradation in the stressed and control samples were estimated 
relative to this assay value. 
Linearity. The linearity was evaluated with 10 standard 
solutions: 5.0, 10.0, 15.0, 20.0, 35.0, 50.0, 60.0, 70.0, 80.0 and 
90.0 |Xg ml-'. The determination was repeated five times at each 
concentration level, 
Limit of detection (LOD) and quantitation (LOQj. The limits of 
detection (LOD) and quantitation (LOQ) for the assay were 
calculated using the equations:14 
LOD = 3.3 x S,Jb and LOQ = 10 x SJb 
where So and b are the standard deviation and the slope of the 
calibration line. 
Precision and accuracy. Intra-day precision and accuracy of 
the proposed method were evaluated by replicate analysis (n = 
5) of calibration standards at three concentration levels (20.0, 
50.0, and 80.0 pig mH). Inter-day precision and accuracy were 
determined by assaying the calibration standards at the same 
concentration levels on five consecutive days. Precision and 
accuracy were based on the calculated relative standard 
deviation (RSD, %) and relative error (RE, %) of the found 
concentration compared to the theoretical one, respectively. 
Recovery studies. The recovery of pantoprazole from 
commercial dosage forms was estimated by the standard 
addition method. For this purpose, a volume of 2.0 ml (or 5.0 
ml) of sample solution was spiked with 2.0, 4.0, 6.0 and 7.0 ml 
(or 1.0, 2.0, 3.0 and 4.0) of reference standard solution (1.0 mg 
ml"') in a 100 ml standard volumetric flask and the mixture was 
diluted up to the mark with distilled water. Each level was 
repeated 5 times. The nominal value was determined by the 
proposed procedure. 
Evaluation of bias. The point and interval hypothesis tests have 
been performed to compare the results of the proposed method 
with those of the reference method at 95% confidence level. 
The bias was evaluated by an interval hypothesis test based on 
the mean values of the proposed method (method 1) and the 
reference method (method 2). The test method is considered 
acceptable when its true mean is within ±2.0% of that of the 
reference method. This can be written as 
0 . 9 8 < M t i < 1-02 
which can be generalized to 
ft < fa/fii < ft 
where ft. and ftj are lower and upper acceptance limits, 
respectively, which were calculated from the following 
quadratic equation:15 
&{pi - SjW/mj + 6[- 2x~^ J + &•{?! - 5?r,ah2/n2) = 0 
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Results and Discussion 
Dialkyl/diaryl/alkyl-aryl sulfoxides undergo oxidation with a 
number of oxidants1617 to form sulfone derivatives. Pantoprazole 
is a sulfoxide derivative that is oxidized in a similar manner by 
ammonium ferric sulfate in moderately acidic medium to form 
pantoprazole sulfone,3 and itself reduces to Fe(II). The reduced 
Fe(II) immediately reacts with potassium ferricyanide, resulting 
in trie formation of Prussian blue product,18 which absorbs 
maximally at 725 nm. The absorbance of the colored solution 
increases with time and hence, a kinetically-based 
spectrophotometric method was elaborated to assay the 
pantoprazole in pharmaceutical formulations. The various 
experimental parameters affecting the formation of colored 
product were optimized and used throughout the experiment. 
TLC study of pantoprazole and its oxidized product 
To identify pantoprazole and pantoprazole sulfone, we used 
thin layer chromatography. The reference standard solutions of 
pantoprazole or of pantoprazole sulfone was applied on TLC 
plates coated with silica gel G (Merck, India) and developed in 
chloroform-methanol (10:0.7 v/v) solvent system. The plates 
were free from mobile phase, dried and spots were detected in 
iodine chamber. The Rf values were 0.54 and 0.66 for 
pantoprazole and pantoprazole sulfone, respectively. The Rf 
value (0.66) of the reaction product confirmed the presence of 
pantoprazole sulfone. 
Optimization of variables 
The optimum conditions for the proposed method responsible 
for the formation of the blue product were studied and 
maintained throughout the experiment. 
Effect of temperature. The effect of temperature on the initial 
rate of reaction was studied at 303, 308, 313 and 318 K. The 
absorbance-time curves showed that the reaction rate increases 
with increase in temperature. At temperature > 313 K, the linear 
dynamic range of determination decreases. The linear dynamic 
range, regression equation and correlation coefficient obtained 
at different temperatures are summarized in Table 1. The best 
linearity was obtained at 308 K and hence this temperature was 
selected as an optimum temperature for the determination process. 
Effect of ammonium ferric sulfate concentration. The effect of 
ammonium ferric sulfate concentration on the initial rate of 
reaction (v) was studied in the range of 2.40 x 10"* - 6.60 x 10"4 
M keeping constant [potassium ferricyanide] = 3.75 x \0~A M 
and [pantoprazole] = 2.09 x \0~4 M. The initial rate of reaction 
increased with increase in the concentration of ammonium ferric 
sulfate and became constant at 3.90 x Kr4 M, and remained as 
such up to 6.60 x 10"* M. The results are summarized in Table 
2. Therefore, a concentration of 5.10 x lO-4 M ammonium 
ferric sulfate was recommended for the determination procedure. 
Effect of potassium ferricyanide concentration. The effect of 
potassium ferricyanide concentration on the initial rate of 
reaction (v) was investigated in the range of 2.50 x 10~5 - 5.00 x 
\Q~* M. The maximum value of the initial rate of reaction was 
obtained with 2.25 x lfj-4 M potassium ferricyanide, after which 
further increase in the concentration of potassium ferricyanide 
up to 5.00 x 10-4 M resulted in no change in the initial rate of 
reaction (Table 2). Thus, the concentration of 3.75 x 10"4 M 
potassium ferricyanide was found to be most suitable 
concentration for the determination process. 
Analytical data and method validation 
The oxidation of pantoprazole takes place with Fe(III) in 
Table 1 Linear dynamic range, regression equation and 
correlation coefficient at different temperatures 
Temp./K Beer's law range/ Kg ml"1 
Regression 
equation 
Correlation 
coefficient, r 
303 
308 
313 
318 
10.0-90.0 
/i = 9 
5.0-90.0 
n- 10 
5.0-90.0 
«=10 
5.0-70.0 
n = 8 
v = -4.615 xlO-6+ 
1.548 xl0"'C 
v = 3.467 x lfr6 + 
4.356 x 10-5C 
v = 2.333x10-' + 
5.606 x 10-5C 
v = 2.455 xl0-5 + 
6.559 x 10"5C 
0.9993 
0.9999 
0.9995 
0.9998 
Table 2 Effect of the concentrations of ammonium ferric 
sulfate and potassium ferricyanide on the initial rate of reaction 
at [pantoprazole] = 2.086 x 10"4 M 
Ammonium ferric sulfate" 
Concentration, 
C/mol 1-' 
2.40x10-" 
3.00 x 10-* 
3.60 xlO"4 
3.90 xlO-4 
4.50 xlO"4 
5.10 xlO"4 
6.60 x 10-1 
Initial rate 
of reaction, 
v/mol I"1 s"' 
2.98 x 10-4 
5.95 x Kr4 
8.77x10-" 
1.24x10-' 
1.24xl0-J 
1.24 x 10-1 
1.24 x 10"' 
Potassium 
Concentration 
C/mol 1-' 
2.50 x 10-5 
5.00 x 10-' 
1.00 xlO4 
1.25 xlO4 
1.75x10-" 
2.25 x Kr4 
2.75 xlO-1 
3.25 x \0r* 
3.75 x 10-4 
5.00 xlO-* 
ferricyanideb 
Initial rate 
of reaction, 
v/mol 1"' s'1 
1.07 xlO4 
2.52 x 10-1 
4.27 xlO-1 
6.66 x 104 
1.15xl0-3 
1.24 xlO-1 
1.24 xlO"3 
1.24 xlO"3 
1.24 xlO"3 
1.24 xlO"3 
a. Keeping constant [potassium ferricyanide] = 3.75 x 10-* M. 
b. Keeping constant [ammonium ferric sulfate] = 5.10 x 10-* M. 
Table 3 Initial rate of reaction for different concentrations of 
pantoprazole with [Fe(III)] = 5.10 x 10-" M and [potassium 
ferricyanide] = 3.75 x 10-1 M at 308 K 
M-g ml-
5.0 
10.0 
15.0 
20.0 
35.0 
50.0 
60.0 
70.0 
80.0 
90.0 
'antoprazole 
mol I"1 
1.304 x 10"' 
2.608x10-' 
3.912x10-' 
5.216x10"' 
9.128x10"' 
1.304 xlO"4 
1.564 x 10-4 
1.825 x 10-" 
2.087 x 10-1 
2.347 x 10-1 
Initial rate of reaction, vl 
u.g ml-1 s"1 
2.166 xlO-1 
4.416 xlO"4 
6.583 x 10"4 
8.750 x 10-" 
1.520 xlO"3 
2.170x10-' 
2.660 x 10-' 
3.050 x 10-' 
3.500x10-' 
3.900x10-' 
acidic medium, resulting in the formation of pantoprazole 
sulfone; subsequently, reduced Fe(II) reacts with potassium 
ferricyanide to form the blue product. The course of the 
reaction was followed spectrophotometrically at 725 nm. The 
initial rates of reaction for different concentrations of 
pantoprazole at 308 K were determined from the slopes of the 
initial tangent to the absorbance-time curves (Fig. 1); these rates 
are summarized in Table 3. The kinetic equation for the 
reaction of pantoprazole with Fe(III) and potassium ferricyanide 
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1.8-
1.6-
1.4-
1.0-
0.8-
0.6-
0.4-
0.2-
OOC 
-•- • 
- O - b 
—T- C 
-<?- d 
- • - 5 
- O - h 
S^^^^—-~* 
^ ^ ^ ^ ^ ^ " ^ 
=s=8 — 
Table 4 Test of precision (intra and inter day assays) for 
analyses of pantoprazole 
rime (min) 
Fig. 1 Absorbance-time curves for the initial rate of reaction of 
pantoprazole: 5.10 x 1CH M ammonium ferric sulfate and 3.75 x lCr4 
M potassium ferricyanide with (a) 5.0, (b) 10.0, (c) 15.0, (d) 20.0, (e) 
35.0, (0 50.0, (g) 60.0, (h) 70.0, (i) 80.0 and (j) 90.0 ug ml-' of 
pantoprazole. 
is written as: 
v= • 
Ax_ 
At 
'• k\ CunigCFcdlllCf, fcnityantjt;. H) 
Under the optimized experimental condit ions, i.e. CFC<HI) > 5.10 
x.,10 -4 M and Cfcrricyll„iae £ 3.75 x 10"4 M the reaction became 
pseudo-zero order with respect to the reagent concentrations. 
Therefore, the above equation reduced to v - k,Co„lf} where k, 
is the first rate constant and n is the order of the reaction. The 
order with respect to pantoprazole was evaluated from the plot 
of log v versus log C and was found to be I. 
Hence, the reaction would obey the pseudo-fmi order 
condition and thus the above equation reduced to v = /ciCnmu-
A calibration graph was constructed by plotting the initial rate 
of reaction (v) versus the pantoprazole concentration (C); the 
graph showed a linear relationship over the concentration range 
of 5.0 - 90.0 (J.g ml"' at 308 K. The regression of initial rate 
versus C gave a linear regression equation, v = 3.467 x I0~* + 
4.356 x 10-5C with coefficient of correlation, r = 0 .9999. The 
confidence limits for the slope of the line of regression and 
intercept were computed using the relation b + tSb and a ± fSa at 
9 5 % confidence level and were found to be 4 .356 x 10"5 ± 4.806 
x lO"7 and 3.467 x 10"* ± 2.519 x 10"5, respectively. The values 
of confidence limits for slope and intercept indicated the high 
reproducibility of the initial rate method. The limits of 
detection (LOD) and quantitation (LOQ) were found to be 1.46 
and 4.43 | ig ml - 1 , respectively. The small value of variance 
(3.716 x I0~10 (ig ml- ' ) also confirmed the negligible scattering 
of the calibration data points around the line of regression. 
Solution stability and selectivity 
Pantoprazole is stable under neutral to moderately acidic 
conditions (pH - 3 . 5 - 7 . 4 ) . 1 9 The solution stability of 
pantoprazole was checked by observing UV spectra of 
pantoprazole for 14 h. The aqueous solution of the drug having 
Am,, at 298 nm showed no changes in the absorption spectra of 
standard and quality control sample solutions of drug for at least 
14 h, when the solutions were stored at a temperature < 45 °C. 
Proposed 
method 
Intra-day assay 
Inter-day assay 
Concentration/fig ml'1 
Taken Found x SD* 
20.0 
50.0 
80.0 
20.0 
50.0 
80.0 
20.0110.05 
49.95 ±0.09 
80.0010.08 
19.9510.15 
49.95 10.09 
80.01 10.16 
RSD", % 
0.24 
0.18 
0.09 
0.78 
0.19 
0.20 
SAP 
0.021 
0.041 
0.033 
0.069 
0.041 
0.071 
C.L.C 
0.059 
0.113 
0.093 
0.192 
0.116 
0.198 
a. Mean for 5 independent analyses. 
b. SAE, standard analytical error. 
c. C.L., confidence limit at 95% confidence level and 4 degrees of 
freedom (t = 2.776). 
To identify pantoprazole and pantoprazole sulfone, we used thin 
layer chromatography. The standard solution, quality control 
sample solution and oxidized product of pantoprazole were 
applied on T L C plates coated with silica gel and developed in 
chloroform-methanol (10:0.7 v/v) solvent system. The plates 
were air-dried and spots were detected in the iodine chamber. 
In the case of standard and quality control sample solutions, a 
single spot was observed with R, = 0.54 corresponding to 
pantoprazole, whereas the oxidized product showed one spot 
with Rf value of 0.66, confirming the presence of pantoprazole 
sulfone. The proposed kinetic method is a selective one, since 
the major metabolite of pantoprazole i.e. pantoprazole sulfone 
does not interfere with the determination process. 
Robustness 
The robustness of the proposed method was investigated by 
challenging each operational parameter such as: 1.7 ml of 0.003 
M ammonium ferric sulfate in 0.003 M H 2 S 0 4 (±0.4 ml); 1.5 ml 
of 0.0025 M potassium ferricyanide (±0.5 ml) ; 35°C (308 K) as 
the working temperature (±1°C). 
Under these conditions quality control sample solutions from 
two commercial dosage forms claiminig 60.0 | ig ml"1 of active 
pantoprazole were assayed by performing 5 independent 
analyses following the proposed kinetic method. The recovery 
results are appreciable with low values of standard deviation 
and relative standard deviat ions. 
Accuracy and precision 
The accuracy and precision of the proposed kinetic method 
were established by performing 5 independent analyses of 
pantoprazole in pure form at three different concentration levels 
(20, 50 and 80 | ig ml"1) by intra-day and inter-day precisions. 
The recovery results with relative standard deviation, standard 
analytical error and confidence limit are summarized in Table 4; 
they confirm that the accuracy and precision were acceptable. 
Thus the proposed method is effective for the estimation of 
pantoprazole. 
The accuracy of the proposed kinetic method was also tested 
by performing recovery exper iments through the standard 
addition method. The recovery was evaluated either by dividing 
the intercept by the slope value of the line of linear regression of 
the standard addition method or by the extrapolation of the same 
line of best fit (Figs. 2 and 3, Table 5). It is evident from Table 
5 that the linearity of the regression line of the standard addition 
method was good. The attractive feature of the method is its 
relative freedom from interference by the usual tablet diluents 
and excipients in amounts far in excess of their normal 
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Table 5 Test of accuracy for analysis of pantoprazole in drug formulations by standard addition method 
Formulation 
Pantec 20 
(Concept) 
Pantodac 20 
(Zydus Cadila) 
Theoretical 
20.0 
50.0 
20.0 
50.0 
Concentration/pig ml-' 
Spiked 
0, 20, 40, 60, 70 
0,10,20,30,40 
0, 20,40, 60, 70 
0, 10,20,30,40 
Nominal 
20.004 
50.242 
20.357 
50.233 
Coefficients of linear regression equation 
of standard addition 
Intercept 
8.766 x 10"1 
2.180 xlO-3 
8.729 xlO-4 
2.150x10-' 
Slope 
4.383 x 10-' 
4.339 x 10-' 
4.365x10"' 
4.280 x 10"' 
r 
0.9999 
0.9994 
0.9998 
0.9998 
Recovery, % 
100.02 
100.48 
99.99 
100.46 
a. Coefficient of correlation. 
Table 6 Analysis of pantoprazole in commercial dosage forms by proposed method and reference method at 95% confidence level 
Formulation 
Pantec 20 (Concept) 
Pantodac 20 (Zydus Cadila) 
Proposed method 
Rec, % RSD, %• 
99.99 0.10 
100.06 0.10 
Reference method 
Rec, % RSD, %• 
100.05 0.10 
99.98 0.10 
Paired (-valueh 
0.114 
0.279 
F-value" 
1.038 
1.201 
0LC 
0.989 
0.991 
9c' 
1.009 
1.011 
a. Mean for 5 independent analyses, b. Theoretical (-value {v - 8) and F-value (v = 4, 4) at 95% confidence level are 2.306 and 6.39, 
respectively, c. In pharmaceutical analysis, a bias, based on recovery experiments, of+2% is acceptable. 
occurrence in pharmaceutical preparations. 
Applicability of the proposed kinetic method 
The proposed kinetic method has been successfully applied to 
the determination of pantoprazole in pharmaceutical 
preparations. The results obtained by the proposed method 
were compared to those of the reference method" using point 
and interval hypothesis tests. The results (Table 6) show that 
the Student's t- and /•'-values at 95% confidence level are less 
than the theoretical values, which confirmed that there is no 
significant difference between the performance of the proposed 
kinetic method and the reference method. The interval 
hypothesis test has also confirmed that no significant difference 
exists between the performances of the methods compared, as 
the true bias of all drug samples is < +2.0%. 
The performance of the proposed kinetic spectrophotometric 
method was compared with other existing conventional 
spectrophotometric methods (Table 7). It is apparent from 
Table 7 that the present procedure requires 4 min only for 
obtaining the initial rate of reaction, which is proportional to the 
concentration of pantoprazole. The reaction of pantoprazole 
with ammonium ferric sulfate and potassium ferricyanide 
requires 30 min to develop a stable color, which is mandatory 
for conventional spectrophotometric methods. Thus, the time of 
analysis is reduced when the kinetic spectrophotometric 
procedure was applied. The other conventional 
spectrophotometric methods using FeCh10 and eosin and 
copper" need longer times to record the absorbance, whereas 
the method utilizing 2,3-dichloro-5,6-dicyano-l,4-
benzoquinone" gives a stable color instantaneously. The 
drawback of these methods is that they employ an organic 
solvent while the proposed kinetic method is carried in an 
aqueous system. 
ANALYTICAL SCIENCES JULY 2006, VOL. 22 
Table 7 Comparison of the proposed kinetic spectrophotometry method with existing conventional spectrophotometry methods for 
the assay of pantoprazole in pharmaceutical formulations 
Reagent 
FeCli in ethanol 
2,3-Dichloro-5,6-dicyano-1,4-
benzoquinone in acetonitrile 
Iodine in chloroform 
Copper and eosin in chloroform 
Potassium ferricyanide and 
ammonium ferric sulfate 
Atnax' 
nm 
455 
457 
359 
549 
725 
Reaction time 
30 min at 60°C 
Immediately at25"C 
5 minat25°C 
25 min at 70°C 
4 min at 35°C 
Linear dynamic 
range/ug ml"1 
30 - 300 
10-60 
17.7- 141.6 
4.3-25.9 
5 -90 
RSD, % 
1.52 
0.53 
1.21 
0.81 
0.78 
Ref. 
10 
11 
11 
11 
This work 
Conclusions 
The proposed kinetic method is a selective one as the drug 
contains sulfoxide group, which preferentially reduces Fe(lll) to 
Fe(Il); subsequently Fe(II) reacts with potassium ferricyanide to 
form Prussian blue. In human and animals, pantoprazole is 
metabolized to pantoprazole sulfone, which did not give a 
positive result with the reagents used. This is a remarkable 
advantage of the method that Fe(III) in the presence of 
potassium ferricyanide selectively reacts with pantoprazole and 
give Prussian blue product. Point and interval hypothesis tests 
clearly proved that the proposed method has acceptable 
recovery with a bias of less than ±2%. The method is also 
useful due to its wide linear dynamic range (5.0 - 90.0 ng ml-1) 
and high tolerance limit for common excipients found in drug 
formulations. Hence, these advantages encourage the 
application of the proposed kinetic method in routine quality 
control analysis of pantoprazole in industries, research 
laboratories and hospitals. 
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